UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K/A
(Amendment No. 1)
(Mark One)
x
|
|
ANNUAL REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
|
|
|
|
|
For the fiscal year
ended
December 31, 2007.
|
|
|
or
|
|
|
|
o
|
|
TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
For the transition
period from
to
.
|
Commission File Number
001-33465
SIRTRIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
20-1410189
|
(State or other
jurisdiction of incorporation or
|
|
(IRS Employer
Identification Number)
|
organization)
|
|
|
|
|
|
200
Technology Square
|
|
|
Cambridge,
Massachusetts
|
|
02139
|
(Address of
Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(617) 252-6920
Securities registered pursuant to Section 12(b) of
the Act:
None
Securities registered pursuant to Section 12(g) of
the Act:
Common Stock, par value $0.001
(Title of Class)
Indicate by check mark if
the registrant is a well-known seasoned issuer, as defined in Rule 405 of
the Securities Act. Yes
o
No
x
Indicate by check mark if the registrant is not
required to file reports pursuant to Section 13 or Section 15(d) of
the Act. Yes
o
No
x
Note
Checking
the box above will not relieve any registrant required to file reports pursuant
to Section 13 or Section 15(d) of the Act from their obligations
under those Sections.
Indicate by check mark whether the registrant (1) has
filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past
90 days. Yes
x
No
o
Indicate by check mark if disclosure of delinquent
filers pursuant to Item 405 of Regulation S-K is not contained
herein, and will not be contained, to the best of registrants knowledge, in definitive
proxy or information statements incorporated by reference in Part III of
this Form 10-K or any amendment to this Form 10-K.
o
Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer, or a
smaller reporting company. See definitions of large accelerated filer, accelerated
filer, and smaller reporting company in Rule 12b-2 of the Exchange
Act. (Check one):
Large
accelerated
filer
o
|
|
Accelerated
filer
o
|
|
Non-accelerated
filer
x
|
|
Smaller
reporting company
o
|
|
|
|
|
(Do not check if a smaller
reporting company)
|
|
|
Indicate by check mark
whether the registrant is a shell company (as defined in Rule 12b-2 of the
Act). Yes
o
No
x
The aggregate market
value of voting common equity of the registrant held by non-affiliates of the
registrant was approximately $137,101,880, on June 29, 2007. For purposes
of the foregoing sentence, the term affiliate includes each director and
executive officer of the registrant and each holder of more than 5% of the
registrants common stock. The computation of the aggregate market value is
based upon the closing price of the common stock as reported on the NASDAQ
Global Market on June 29, 2007.
As of April 22,
2008, the registrant had 29,265,532 shares of common stock, par value $0.001
per share, outstanding.
SIRTRIS
PHARMACEUTICALS, INC.
Amendment No. 1 to
2007
Annual Report on Form 10-K/A
Table
of Contents
Explanatory
Note
We are filing this amendment (this Amendment) to our
Annual Report on Form 10K for the fiscal year ended December 31, 2007 (fiscal
2007 10K) because we do not anticipate filing the Proxy Statement for our
2008 Annual Meeting of Stockholders (2008 Proxy Statement) within 120 days
after the end of the fiscal year covered by the fiscal 2007 10K. Information
in this amendment is therefore intended to amend Part III (Items 10, 11, 12, 13
and 14) in the fiscal 2007 10K which had previously incorporated the 2008
Proxy Statement by reference. This report is limited in scope to the items
identified above and should be read in conjunction with the fiscal 2007 10K.
Other than the furnishing of the information identified above, this report does
not modify or update the disclosure in the fiscal 2007 10K in any way.
1
Item
10. Directors and Executive Officers
The following table sets forth information concerning
our directors as of April 22, 2008:
Name
|
|
Age
|
|
Biography
|
Richard Aldrich
|
|
53
|
|
Mr. Aldrich
has served as a member of our Board of Directors since 2004. Mr. Aldrich
is Chairman of RA Capital Management, LLC, an investment firm with which he
has been affiliated since 2001. Mr. Aldrich previously joined Vertex
Pharmaceuticals Inc. at its founding in 1989 and served as Senior Vice
President and Chief Business Officer, from 1991 to 2001. He serves on the
boards of directors of Concert Pharmaceuticals, Inc., and Magen
BioSciences, Inc.
|
|
|
|
|
|
Jeffrey Capello
|
|
43
|
|
Mr. Capello
has served as a member of our Board of Directors since January 2008.
Mr. Capello has been the Senior Vice President and Chief Financial
Officer at PerkinElmer, Inc. since January 2006. Prior to that
position, he served as PerkinElmers Chief Accounting Officer from
April 2002 to January 2006 and as Vice President of Finance,
Corporate Controller and Treasurer from June 2001 to April 2002.
From 1991 to June 2001, he held various positions including that of
partner from 1997 to 2001 at PricewaterhouseCoopers LLP, a public accounting
firm, initially in the United States and later in the Netherlands. He holds a
Bachelor of Science degree in business administration from the University of
Vermont and a Master of Business Administration degree from the Harvard
Business School.
|
|
|
|
|
|
John Clarke
|
|
54
|
|
Mr. Clarke
has served as a member of our Board of Directors since 2004. Mr. Clarke
has been a Managing General Partner of Cardinal Partners, a venture capital
firm, since 1997. Prior to founding Cardinal Partners, Mr. Clarke was a
General Partner of DSV Partners, a venture capital firm he joined in 1982.
Mr. Clarke was a founder and former Chairman and CEO of Cubist
Pharmaceuticals, Inc. and a founder and former director of
Alkermes, Inc. Mr. Clarke is Chairman of the Board of Directors of
Alnylam Pharmaceuticals, Inc. and aTyr Pharma, Inc. and also serves
on the Board of Directors of Momenta Pharmaceuticals, Inc.,
Visicu, Inc. and several other private health care companies.
Mr. Clarke also serves on the boards of The Jackson Laboratory, a
nonprofit research institute, and HandsTogether, a non profit development
organization focused on humanitarian, health care and educational aid for the
people of Haiti.
|
|
|
|
|
|
Paul Friedman,
M.D.
|
|
65
|
|
Dr. Friedman
has served as a member of our Board of Directors since March 2008.
Dr. Friedman has served since 2001 as president and chief executive
officer of Incyte Corporation, a biotechnology company. From 1998 until
October 2001, Dr. Friedman served as President of DuPont
Pharmaceuticals Research Laboratories, a wholly owned subsidiary of DuPont
Pharmaceuticals Company (formerly The DuPont Merck Pharmaceutical Company),
from 1994 to 1998 he served as President of Research and Development of The
DuPont Merck Pharmaceutical Company, and from 1991 to 1994 he served as
Senior Vice President at Merck Research Laboratories. Prior to his work at
Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine
and Pharmacology at Harvard Medical School. Dr. Friedman is a Diplomat
of the American Board of Internal Medicine and a Member of the American
Society of Clinical Investigation.
|
|
|
|
|
|
Stephen Hoffman,
Ph.D., M.D.
|
|
54
|
|
Dr. Hoffman
has served as a member of our Board of Directors since 2004. From 2003 to
March 2007, Dr. Hoffman was employed by TVM Capital. In
April 2007 he joined Skyline Ventures as Managing Director. He also
currently serves as Chairman of Allos Therapeutics, Inc., a
biopharmaceutical company where he served as Chief Executive Officer from
1994 to 2001 and as Executive Chairman from 2001 to 2002. Dr. Hoffman
serves on the boards of directors of Concert Pharmaceuticals, Inc.,
|
2
|
|
|
|
Tolerx
Pharmaceuticals, Inc. and Dicerna Pharmaceuticals, Inc.
|
|
|
|
|
|
Richard Pops
|
|
46
|
|
Mr. Pops is
a founder of Sirtris, a Class II director with a term expiring in 2009
and has served as a member of our Board of Directors since 2004.
Mr. Pops was the Chief Executive Officer of Alkermes, Inc., a
biotechnology company, from 1991 to 2007 and currently serves as the Chairman
of Alkermes. He serves on the boards of directors of Acceleron
Pharma, Inc., CombinatoRx, Inc., and Neurocrine
Biosciences, Inc.
|
|
|
|
|
|
Paul Schimmel,
Ph.D.
|
|
67
|
|
Dr. Schimmel
is a founder of Sirtris and has served as a member of our Board of Directors
since 2004. Dr. Schimmel is the Ernest and Jean Hahn Professor at The
Skaggs Institute for Chemical Biology at The Scripps Research Institute. He
formerly was the John D. and Catherine T. MacArthur Professor of Biochemistry
and Biophysics in the Department of Biology at the Massachusetts Institute of
Technology. Dr. Schimmel is a member of the National Academy of Sciences
and has co-founded a number of biotechnology companies including
Alkermes, Inc. and Alnylam Pharmaceuticals, Inc. He serves on the
boards of directors of Alnylam Pharmaceuticals, Inc., aTyr
Pharma, Inc., and Avicena Group.
|
|
|
|
|
|
David Sinclair,
Ph.D. (38)
|
|
38
|
|
Dr. Sinclair
is a founder of Sirtris and has served as a member of our Board of Directors
since 2004. Dr. Sinclair is an Associate Professor of Pathology at
Harvard Medical School, and Director of the Glenn Laboratories for the
Biological Mechanisms of Aging. He has made key contributions to the scientific
understanding of aging. In 1997, he identified a cause of aging in yeast, a
first for any species, and in 2003 reported the discovery of a conserved
master regulatory gene controlling this process. His laboratory at Harvard is
currently focused on slowing diseases of aging in mammals using genetic and
pharmacological means. Dr. Sinclair has authored over 50 peer-reviewed
scientific publications, including several seminal papers in
Nature
,
Cell
and
Science
. He has received
numerous awards and honors for his research. Dr. Sinclair performed his
post-doctoral work with Dr. Leonard Guarente at the Massachusetts
Institute of Technology and holds a Ph.D. in Biochemistry and Molecular
Genetics from the University of New South Wales, Australia.
|
|
|
|
|
|
Christoph
Westphal, M.D., Ph.D.
|
|
40
|
|
Dr. Westphal
is a founder of Sirtris and has served as President, CEO and Vice Chairman of
our Board of Directors since 2004. Dr. Westphal was previously a venture
capitalist with Polaris Venture Partners from 2000 until 2005; and a
consultant with McKinsey & Company from 1998 to 2000.
Dr. Westphal co-founded Acceleron Pharma, Inc., Alnylam
Pharmaceuticals, Inc. and Momenta Pharmaceuticals, Inc., as CEO and
Vice Chairman. Dr. Westphal received his M.D., Ph.D. from Harvard Medical
School.
|
The following table sets forth information concerning
our executive officers as of April 22, 2008:
Name
|
|
Age
|
|
Position
|
|
|
|
|
|
Christoph
Westphal, M.D., Ph.D.
|
|
40
|
|
President and
Chief Executive Officer, Vice Chair
|
Garen Bohlin
|
|
60
|
|
Chief Operating
Officer
|
Peter Elliott,
Ph.D.
|
|
49
|
|
Senior Vice
President, Head of Development
|
Michael
Jirousek, Ph.D.
|
|
49
|
|
Senior Vice
President, Research
|
Christoph
Westphal, M.D., Ph.D.
is a founder of Sirtris and has served
as CEO and Vice Chairman of our Board of Directors since 2004. Dr. Westphal
was previously a venture capitalist with Polaris Venture Partners from 2000
until 2005; and a consultant with McKinsey & Company from 1998 to
2000. Dr. Westphal co-founded Acceleron Pharma, Inc., Alnylam
Pharmaceuticals, Inc. and Momenta Pharmaceuticals, Inc., as CEO and
Vice Chairman. Dr. Westphal received his
3
M.D., Ph.D. from Harvard Medical School.
Garen
Bohlin
has served as our Chief Operating Officer since 2006.
Prior to joining Sirtris, Mr. Bohlin served as President and Chief
Executive Officer of Syntonix Pharmaceuticals, Inc. from 1999 to 2005.
Prior to Syntonix, which was acquired by Biogen Idec in 2006, Mr. Bohlin
spent 14 years in executive management at Genetics Institute, Inc. In his
last role at Genetics Institute, Mr. Bohlin served as Executive Vice
President with responsibility for most of the non-scientific areas of the
company that comprised approximately half of the companys then 1,600
employees. Mr. Bohlin played a leading role in structuring and
implementing a strategic alliance with American Home Products (now Wyeth) that
resulted in the eventual acquisition of Genetics Institute at an implied
valuation of approximately $3 billion. Prior to Mr. Bohlins tenure at
Genetics Institute, he was a partner at Arthur Andersen & Co., where
he spent 13 years. Mr. Bohlin serves as a director of Acusphere, Inc.
and Targanta Therapeutics, Corp.
Peter
Elliott, Ph.D.
has served as our Senior Vice President, Head
of Development since 2005. Prior to joining Sirtris, from 2001 through 2005, Dr. Elliott
held various positions at CombinatoRx, Inc., a biopharmaceutical company,
including Executive Vice President of Product Development. Dr. Elliott was
Vice President of Pharmacology and Drug Development at Millennium
Pharmaceuticals, Inc. from 1998 to 2001. Prior to Millennium, Dr. Elliott
spent four years at Alkermes, Inc. and five years at GSK in the United
Kingdom. Dr. Elliott holds a B.S. in Pharmacology from London University,
an M.Phil. in Pharmacology from Cambridge University, and a Ph.D. in
Psychopharmacology from Cambridge University.
Michael Jirousek, Ph.D.
has
served as our Senior Vice President, Research since 2006. From 2001 to 2006,
Dr. Jirousek served as Senior Director and Head of the Diabetes Therapeutic
Area for Pfizer Inc. at its La Jolla laboratories. From 1998 to 2001, Dr.
Jirousek was at Abbott Laboratories as a Metabolic Department Head and prior to
that at Eli Lilly in Indianapolis, Indiana and Hamburg, Germany. Dr. Jirousek
was a post-doctoral research Fellow at Harvard University. Dr. Jirousek holds a
Ph.D. in Chemistry from Case Western University.
Board
Meetings and Participation
Our Board of Directors held ten regular meetings and
no special meetings during fiscal 2007. Each of the directors attended at least
75% of the total number of meetings of the Board held while he was a director
and all committees of the Board of Directors on which he served. The Board of
Directors does not have a formal policy requiring attendance by the directors
at the annual meetings of stockholders. None of the members of the Board of
Directors attended our 2007 annual meeting.
Director
Independence
As required by the listing standards of the NASDAQ
Stock Market (NASDAQ), the Board of Directors has determined, upon the
recommendation of the Nominating and Corporate Governance Committee, that each
of Messrs. Aldrich, Capello, Clarke and Pops and Drs. Friedman,
Hoffman and Schimmel are independent within the meaning of the rules and
regulations of NASDAQ. To make this determination, our Board of Directors
reviews all relevant transactions or relationships between each director, and
Sirtris, its senior management and its independent auditors. During this review,
the Board considers whether there are any transactions or relationships between
directors or any member of their immediate family (or any entity of which a
director or an immediate family member is an executive officer, general partner
or significant equity holder) and members of our senior management or their
affiliates. The Board consults with the Companys corporate counsel to ensure
that the Boards determinations are consistent with all relevant securities and
other laws and regulations regarding the definition of independent, including
those set forth in pertinent NASDAQ listing standards, as in effect from time
to time.
Board
Committees
The Board of Directors has a standing Audit Committee,
Compensation Committee and Nominating and Corporate Governance Committee. Each
of the Audit Committee, Compensation Committee and Nominating and Corporate
Governance Committee acts pursuant to a written charter. Current copies of the
charters of each of the committees are available in the Investor Relations-Corporate
Governance section of our website at
www.sirtrispharma.com
.
The members, functions and other information about the
committees of our Board are as follows:
Audit
Committee
The Audit Committee provides the Board of Directors
with an independent review of our financial health and of the reliability of
our financial controls and financial reporting systems. The Audit Committee
consists of Mr. Capello (chairperson), Mr. Clarke and Mr. Pops. Dr. Freund
was a member of the Audit Committee until his resignation from the Board of
Directors in January 2008. Dr. Schimmel was a member of the Audit
Committee until April 2008 when he was replaced by Mr. Pops. The Audit Committee reviews our financial
controls, evaluates the scope of the annual audit, reviews audit results,
consults with management and our independent accountants prior to the
presentation of financial
4
statements to stockholders and, as appropriate,
initiates inquiries into aspects of our internal accounting controls and
financial affairs. The Audit Committee has sole and direct responsibility for
appointing, evaluating and retaining our independent auditors, including
overseeing their work, determining their fees and implementing an approval process
for any non-audit services. During the fiscal year ended December 31,
2007, the Audit Committee met four times. The report of the Audit Committee is
included in this Annual Report on Form 10-K/A under Report of the Audit
Committee. The Board of Directors has determined, upon recommendation of the
Nominating and Corporate Governance Committee, that each member of Sirtris
Audit Committee other than Dr. Schimmel satisfies the requirements for
membership established by the NASDAQ Global Market and the SEC. The Board of
Directors has determined, upon recommendation of the Nominating and Corporate
Governance Committee, that each of Mr. Clarke, Mr. Capello and Mr.
Pops is an audit committee financial expert within the meaning of the rules and
regulations of the SEC.
Compensation
Committee
The Compensation Committee determines salaries,
incentives and other compensation for our directors and executive officers,
including the Chief Executive Officer. The Compensation Committee also
administers incentive compensation and employee benefit plans, including our
Amended and Restated 2004 Incentive Plan (the Plan). The Compensation
Committee consists of Dr. Hoffman (chairperson), Dr. Friedman and Mr. Aldrich.
Dr. Freund was a member of the Compensation Committee until his
resignation from the Board of Directors in January 2008. The Board of
Directors has determined, upon recommendation of the Nominating and Corporate
Governance Committee, that each member of Sirtris Compensation Committee
satisfies the independence requirements established by the rules and
regulations of NASDAQ and the SEC. Pursuant to the Compensation Committees charter,
the Committee has the authority to delegate to subcomittees of the Committee
any of the responsibilities of the full Committee. During the fiscal year ended
December 31, 2007, the Companys Compensation Committee met seven times.
The report of the Compensation Committee is included in this Annual Report on Form
10-K/A under Report of the Compensation Committee. Our Compensation Committee
has engaged a compensation consultant to advise it on executive compensation
matters and provide the Committee with data to benchmark the base salary,
annual performance bonus, and long-term equity incentive compensation of our
named executive officers.
Nominating and Corporate Governance
Committee
The Nominating and Corporate Governance Committee is
responsible for identifying and recommending potential candidates qualified to
become Board members, recommending directors for appointment to Board
committees and developing and recommending to the Board a set of corporate
governance principles. The Nominating and Corporate Governance Committee
consists of Mr. Pops (chairperson), Dr. Hoffman and Mr. Aldrich.
The Board of Directors has determined that each member of Sirtris Nominating
and Corporate Governance Committee satisfies the independence requirements
established by the rules and regulations of NASDAQ and the SEC. During the fiscal year ended December 31,
2007, the Nominating and Corporate Governance Committee met six times.
In identifying and recommending nominees for positions
on the Board of Directors, the Nominating and Corporate Governance Committee
places primary emphasis on a potential candidates qualifications in light of
the expertise of the members already serving on the Companys Board. Additional
factors which the Committee may consider include a candidates specific
experiences and skills, relevant industry background and knowledge, time
availability in light of other commitments, potential conflicts of interest,
material relationships with the Company and independence from management and
the Company. The Nominating and Corporate Governance Committee also may seek to
have the Board represent a diversity of backgrounds, experience, gender and
race.
The Nominating and Corporate Governance Committee does
not set specific, minimum qualifications that nominees must meet in order to be
recommended to the Board of Directors, but rather believes that each nominee
should be evaluated based on his or her individual merits, taking into account
the needs of the Company and the composition of the Board of Directors. Members
of the Nominating and Corporate Governance Committee discuss and evaluate
possible candidates in detail and suggest individuals to explore in more depth.
The Nominating and Corporate Governance Committee regularly reviews existing
Board members that are up for re-election as well as candidates that may either
replace directors that have announced an intention to resign or not stand for
re-election, or to address a new Board competency that the Committee working
together with the Chief Executive Officer has identified. In the case of
existing Board members that are up for re-election, the Committee reviews and
evaluates such individuals and makes its recommendation to the full Board for
approval. In the case of potential new Board members, once a potential
candidate is identified, the Committee members meet with the candidate and, if
they determine that the candidate is viable, all current Board members,
including the Chief Executive Officer, meet with the candidate. The full Board
then reviews and evaluates the candidate and determines whether he or she
should be invited to join the Board of Directors as a member.
The Nominating and Corporate Governance Committee does
not have a formal written policy with regard to candidates recommended by
stockholders for membership on the Board of Directors, but will consider
nominations from stockholders and evaluate a candidate in the same manner as it
evaluates all other nominees.
Section 16(a) Beneficial
Ownership Reporting Compliance
Section 16(a) of the Securities Exchange Act
of 1934, as amended, requires our directors, officers and persons who own more
than ten percent of a registered class of our equity securities, to file with
the Securities and Exchange Commission initial reports of ownership and reports
of changes in ownership of our common stock and other of our equity securities.
Officers, directors and greater than ten percent stockholders are required by
regulations of the Securities and Exchange Commission to furnish us with copies
of all Section 16(a) forms they file.
Based on Sirtris review of the reports it has received, Sirtris
believes that all of its directors, officers and persons owning more than 10%
of Sirtris common stock complied with all reporting requirements applicable to
them with respect to transactions in the fiscal year ended December 31,
2007.
Code of
Ethics and Conduct
Our Company has adopted a Code of Ethics and Conduct
for its employees, officers and directors. A copy of the Code of Ethics and
Conduct can be accessed free of charge by visiting the Investor
Relations-Corporate Governance section of our website at
http://www.sirtrispharma.com
or by requesting a copy in writing to us at Sirtris Pharmaceuticals, Inc.
200 Technology Square, Cambridge, MA 02139, Attention: Investor Relations. The Company intends to disclose any changes
in or waivers from its Code of Ethics and Conduct by posting such information
on its website or by filing a Form 8-K.
5
Item
11. Executive Compensation
COMPENSATION DISCUSSION &
ANALYSIS
Executive
Compensation Philosophy
Primary Objectives
The primary objectives of the Compensation Committee
of our Board of Directors with respect to executive compensation are to
attract, retain, and motivate the best possible executive talent. The focus is
to tie short and long-term cash and equity incentives to the achievement of measurable
corporate and individual performance objectives, and to align executives
incentives with stockholder value creation. To achieve these objectives, the
Compensation Committee has maintained, and expects to further implement,
compensation plans that tie a substantial portion of executive officers
overall compensation to our research, development, and operational performance.
The Compensation Committee has engaged a compensation
consultant to provide general advice and guidance to the Compensation Committee.
The consultants responsibilities include recommending the relevant peer group
to be used for baseline comparisons, providing objective, competitive data
analysis on compensation elements, sharing insight on changing compensation
practices and trends, and educating the Committee on specific details of
compensation alternatives. The consultant reports directly to the Compensation
Committee. The consultants fees are paid by the Company. All services to be
performed by the consultant are approved by the Committee.
Benchmarking for Compensation
In benchmarking our executive compensation program to
ensure that it is competitive, the Compensation Committee, working with its
compensation consultant, typically selects a comparative peer group of approximately
30 companies based on stage of development, types of products under development
and geography, among other factors. This group provides the basis for
benchmarking our executive compensation program, both in the aggregate and
compared by individual components. In applying the peer group data, the
Committee considers whether the comparable Sirtris executive roles vary
significantly in breadth or scope from the equivalent roles in the peer group,
how the executive officers relative experience and tenure in the role compares
to those of the peers and competitive
matters. The Compensation Committee reviews and updates the peer group list
periodically to reflect the most comparable companies. We believe that the
practices of the peer group of companies provide us with appropriate
compensation benchmarks, because these companies have similar organizational
structures and tend to compete with us for executives and other employees. For 2007, our peer group was comprised of the
following companies: Acadia, Achillion, Acorda, Adnexus , Affymax, Alexza,
Alnylam, Amicus, Altus, Archemix, Biodel, Cadence, CombinatoRx, Cytokinetics,
Elixir, Idenix, Insulet, Jazz, Molecular Insight, Momenta, Novacea, Optimer,
Osiris, Pharmasset, Sucampo, Synta, Tercica, Trubion, ViaCell and Xenoport.
Pay-for-Performance Philosophy
Based on these data, the Compensation Committee has
adopted a pay-for-performance compensation philosophy, which is intended to
bring base salaries and total executive compensation in line with the peer group
of the companies represented in the compensation data we review. We work within
the framework of this pay-for-performance philosophy to determine each
component of an executives initial compensation package based on numerous
factors, including:
·
the
individuals particular background and circumstances, including training and
prior relevant work experience;
·
the
individuals role with us and the compensation paid to similar persons in the
companies represented in the compensation data that we review;
·
the
demand and competition for the individual, with the individuals specific
expertise and experience;
·
performance
goals and other expectations for the position; and
·
uniqueness
of industry skills.
Setting and Assessment of Performance Goals
The Compensation Committee has also implemented an
annual performance management program, under which
6
annual performance goals are determined and set forth in writing at the
beginning of each calendar year for the corporation as a whole. Annual
corporate goals are proposed by management, determined by the Committee and
approved by the Board of Directors. These corporate goals include the
achievement of qualitative and quantitative operational and financial targets and
pre-defined research and development milestones. Each goal is weighted as to
importance by the Board of Directors based on a recommendation by the
Compensation Committee. The individual performance of our executive officers is
based on the level of achievement of corporate goals including those related to
their respective areas of responsibility as well as on basic skills such as the
management and development of people, communication, leadership and the use of
sound judgment in performing their responsibilities. Annual salary increases,
annual cash incentive bonuses, and annual stock awards granted to our executive
officers are tied to the achievement of the corporate goals.
We perform an ongoing assessment to determine progress
against the previously established goals and to make any adjustments to the
goals for the remainder of the year based on changing circumstances and
conditions.
At the end of the fourth calendar quarter, we evaluate
individual, department and corporate performance against the goals for the year
coming to a close. Consistent with our compensation philosophy, each executive
officers evaluation begins with a written self-assessment, which is submitted
to the Chief Executive Officer, who then performs the individual evaluations
and submits recommendations to the Compensation Committee for salary increases,
cash incentive bonuses, and stock option awards. In the case of the Chief
Executive Officer, his individual performance evaluation is conducted by the
Compensation Committee. The Board of Directors, based on a recommendation of
the Compensation Committee, approves all salary increases, as well as bonuses
and stock awards, if any, for executive officers. Annual base salary increases,
annual stock awards, and annual cash incentive bonuses, to the extent granted,
are implemented during the first calendar quarter of the following year.
Compensation
Components
We view the three components of our executive
compensation, consisting of base salary, annual cash bonus and long-term
incentives, as related but distinct. Although our Compensation Committee does
review total compensation, we do not believe that significant compensation
derived from one component of compensation should negate or reduce compensation
from other components. We determine the appropriate level for each compensation
component based in part, but not exclusively, on competitive benchmarking
consistent with our recruiting and retention goals, on our view of internal
equity and consistency, individual, department, and corporate performance and
other information we deem relevant, such as the survey data referred to above.
We believe that, as is common in the biopharmaceutical industry, stock awards
are a primary motivator in attracting and retaining executives.
We account for the equity compensation expense for our
employees under the rules of SFAS 123R, which requires us to estimate and
record an expense for each award of equity compensation over the service period
of the award. Accounting rules also require us to record cash compensation
as an expense at the time the obligation is accrued.
Under Section 162(m) of the Internal Revenue
Code, publicly held corporations may be prohibited from deducting as an expense
for federal income tax purposes total compensation in excess of $1 million paid
to certain executive officers in a single year. However, until we achieve
sustained profitability, the availability to us of a tax deduction for
compensation expense is not material to our financial performance. Section 162(m) provides
an exception for qualifying performance-based compensation, including
compensation attributable to certain stock options. The Company expects to keep
nonperformance-based compensation within the $1 million limit in order that
all executive compensation will be fully deductible; however, the valuation of
stock option and restricted stock grants in the future is uncertain and may
cause nonperformance-based compensation to exceed the deductibility limit.
Although the Compensation Committee considers the net cost to the Company in
making all compensation decisions (including, for this purpose, the potential
limitation on deductibility of executive compensation), there is no assurance
that compensation realized with respect to any particular award will qualify as
performance-based compensation. It is not anticipated that any executive
officers annual compensation will exceed $1 million, and the Company has
accordingly not made any plans to qualify for any compensation deductions under
Section 162(m) of the Internal Revenue Code.
The components of our compensation package are as
follows:
Base Salary
Base salaries for our executives are established based
on the scope of their responsibilities and their prior relevant background,
training, and experience, taking into account competitive market compensation
paid by the companies
7
represented in the compensation data we review for similar positions
and the overall market demand for such executives. As with total executive
compensation, we believe that executive base salaries should generally target
the fiftieth to seventy-fifth percentile of the range of salaries for
executives in similar positions and with similar responsibilities in the peer
group companies represented in the compensation data we review and to be
retentive of the executive.
Base salaries are reviewed annually as part of our
performance management program and increased for merit reasons, based on the
executives success in meeting or exceeding individual performance objectives
and an assessment of whether significant corporate goals were achieved. The
individual performance of our executive officers is based on the level of
achievement of corporate goals including those related to their respective
areas of responsibility as well as on core competencies such as the management
and development of people, communication, leadership and the use of sound
judgment in performing their responsibilities. Our corporate goals target the
achievement of certain research, development and operational milestones. If
necessary, we also realign base salaries with market levels for the same
positions in the companies represented in the compensation data in our peer
group, if we identify significant market changes in our data analysis.
Additionally, we adjust base salaries as warranted for promotions or other
changes in the scope or breadth of an executives role or responsibilities. The
Compensation Committees recommendations as to increases in base salary in
fiscal 2008 were reviewed and approved by the Board of Directors in January 2008. Merit salary increases given to our executive
officers ranged from 8.4% to 15.6% of 2007 base salary and included adjustments
for each executive that resulted from increasing the Companys targeted
compensation level from the fiftieth to the seventy-fifth percentile. The merit salary increase for Dr. Westphal,
our Chief Executive Officer, was 15.6%, and reflected the Compensation
Committees view of Dr. Westphals significant efforts and leadership
across all areas of our business, as reflected in the level of achievement
against our corporate goals as well as an adjustment to bring Dr. Westphal
up to the Companys targeted 75
th
percentile compensation level from
the 50
th
percentile.
Annual Bonus
Our compensation program includes eligibility for an
annual performance-based cash bonus in the case of all executives. An executives
bonus payment is based principally on the achievement of the major corporate
goals, with a target bonus generally set as a percentage of base salary to
reward strong performance and retain employees in a competitive labor market.
In fiscal 2007, our corporate goals included research, development and
operational milestones. In fiscal 2007,
the target bonuses for our executive officers ranged from 25% to 35% of their
base salary. Underachievement or
overachievement of the major corporate goals may result in lower or higher
bonus payments. For all executive officers, the annual bonus is based entirely
on the Boards and Compensation Committees assessment that the Company
achieved its corporate goals for the year. Additionally, the Board of
Directors, based on a recommendation of the Compensation Committee, may
increase or decrease an executives bonus payment because of an executives
individual performance during a given year. For 2008, all executives, other
than our Chief Executive Officer are eligible for annual performance-based cash
bonuses with a target of up to 35-40% of their base salaries and our Chief
Executive Officer is eligible for an annual performance-based cash bonus with a
target of up to 60% of his base salary. Targets for bonus compensation were
increased for 2008 based on a review of compensation data from companies in the
Companys peer group. In its discretion, the Compensation Committee may,
however, award bonus payments to our executive officers above or below the
target amount.
Based on the criteria described above, the Board of
Directors approved the Compensation Committees recommendations as to cash
bonuses for certain of our executive officers in January 2008. The annual
cash bonus paid to our named executive officers in January 2008 is set
forth in the Summary Compensation Table following this report. The approved
amounts included a bonus of $183,800 paid to Dr. Westphal, our Chief
Executive Officer, which represented 135% of his target bonus or 47.2% of 2007
base salary. Dr. Westphals bonus was based entirely on the Board and
Compensation Committees assessment that the Company achieved, in the
aggregate, 135% of its corporate goals in 2007.
In April 2008, the Board of Directors, based upon
the recommendation of the Compensation Committee, approved our 2008 corporate
performance goals. The 2008 corporate performance goals include certain
quantitative and qualitative operational and financial targets, clinical and
research and development milestones and business development goals.
Long-Term Incentives
We believe that long-term performance is achieved
through an ownership culture that encourages long-term participation by our
executive officers in equity-based awards. Our Plan allows the grant to
executive officers of stock options, restricted stock, and other equity-based
awards. We typically make an initial equity award of stock options to new
employees and annual equity grants as part of our overall compensation program.
All grants of options and restricted stock to all of our employees, including
executive officers, are recommended by the Compensation Committee and approved
by
8
the Board of Directors.
Initial
stock option awards.
Generally, executives who join us are awarded initial stock option
grants. These grants usually have an exercise price equal to the closing market
value of our common stock as reported on the NASDAQ Global Market on the date
of the grant and a vesting schedule of 25% on the first anniversary of the date
of hire and quarterly thereafter for the next three years. The amount of the
initial stock option award is determined based on the executives position with
us and analysis of the competitive practices of the companies similar in size
to us represented in the compensation data that we review. The initial stock
option awards are intended to provide the executive with incentive to build
value in the organization over an extended period of time. The amount of the
initial stock option award is also reviewed in light of the executives base
salary and other compensation to ensure that the executives total compensation
is in line with our overall compensation philosophy.
Annual
stock option awards.
Our practice is to make annual stock option awards as part of our
overall performance management program. The Compensation Committee believes
that stock options provide management with a strong link to long-term corporate
performance and the creation of stockholder value. We intend that the annual
aggregate value of these awards will be set near competitive levels for
companies represented in our peer group.
As is the case when the amounts of base salary and initial equity awards
are determined, a review of all components of the executives compensation is
conducted when determining annual equity awards to ensure that an executives
total compensation conforms to our overall philosophy and objectives. In addition, in the fourth quarter of 2007,
we undertook an analysis of our executives level of fully diluted ownership of
the Company as a newly publicly traded company as compared to our peer group
and considered the analysis in determining stock option and restricted stock
awards.In January 2008, our executive officers were granted the following
stock options: (a) Christoph Westphal, our President and Chief Executive
Officer, was granted an option to purchase 150,000 shares; (b) Garen
Bohlin, our Chief Operating Officer, was granted an option to purchase 55,000
shares; (c) Peter Elliott, our Senior Vice President, Head of Development,
was granted an option to purchase 42,500 shares; and (d) Michael Jirousek,
our Senior Vice President, Research was granted an option to purchase 32,500
shares. The options vest as to 25% of such shares on January 2, 2009, with
the remainder of shares to vest in equal quarterly installments (rounded down
to the nearest whole share except for the last installment, which shall vest as
to the remaining unvested shares) over the next 12 quarters ending March 31,
June 30, September 30 and December 31 following January 2,
2009.
Restricted common stock.
We have made grants of restricted common
stock to our executive officers to provide additional long-term incentive to
build stockholder value. Grants of restricted common stock are made in
anticipation of contributions that will create value in the Company and are
subject to a lapsing repurchase right by the Company over a period of time. In January 2008,
the Board of Directors awarded our executive officers the following restricted
stock awards: (a) Christoph Westphal, our President and Chief Executive
Officer was awarded 150,000 shares; (b) Garen Bohlin, our Chief Operating
Officer, was awarded 55,000 shares; (c) Peter Elliott, our Senior Vice
President, Head of Development, was awarded 42,500 shares; and (d) Michael
Jirousek, our Senior Vice President, Research was awarded 32,500 shares. The
awards vest as to 20% of such shares on January 1, 2010, 30% of such
shares on January 1, 2011 and 50% of such shares of January 1, 2012,
provided that, the portion of the shares that would otherwise vest on January 1,
2012 will vest earlier if certain pre-defined business development or clinical
goals are met.
Other Compensation
We maintain broad-based benefits and perquisites that
are provided to all eligible employees, including health insurance, life and
disability insurance, dental insurance, and a 401(k) plan. In particular
circumstances, we also utilize cash signing bonuses when certain executives
join us. Whether a signing bonus is paid and the amount thereof is determined
on a case-by-case basis under the specific hiring circumstances. For example,
we will consider paying signing bonuses to compensate for amounts forfeited by
an executive upon terminating prior employment, to assist with relocation
expenses, and/or to create additional incentive for an executive to join our
Company in a position where there is high market demand.
Termination Based Compensation
Severance.
Under certain circumstances specified in
their employment agreements, our executive officers are entitled to receive
severance payments following termination of employment. In determining whether
to approve and setting the terms of such severance arrangements, the
Compensation Committee recognizes that executives, especially highly ranked
executives, often face challenges securing new employment following
termination. Severance for termination without cause or resignation for good
reason for each of our executive officers is 12 months of base salary and a
pro-rated portion of such executive officers targeted cash incentive bonus for
that portion of the year that the executive is employed. We believe that our
9
executive officers severance package is in line with severance
packages offered to executive officers of the companies of similar size to us
represented in the compensation data we reviewed.
Acceleration
of vesting of equity-based awards.
In January of 2008 the Company reviewed
compensation data from companies in its peer group and adjusted the severance
payments and acceleration of equity awards upon a change of control and upon
termination in connection with a change of control to be more consistent with
practices of such companies. In the
event of a change of control, as defined in each of the executive officers new
employment agreements entered into in January of 2008, certain provisions allow
for acceleration of equity awards. Pursuant to our Chief Executive Officers
employment agreement, all of his unvested options and restricted stock shall
immediately vest upon a change of control. For each of the other executive
officers, an additional 25% of his unvested options and restricted stock shall
vest upon a change of control. The remaining unvested options and restricted
stock will vest if the officer is terminated without cause or he resigns for
good reason within one year following the change in control. The four executive
officers may also be entitled to an additional tax gross-up payment for any
excise tax imposed on excess parachute payments under Section 4999 of the
Internal Revenue Code. See Potential Payments and Benefits Upon Termination
and Change in Control for additional information.
Future
Compensation
On April 22, 2008, Sirtris entered into an Agreement
and Plan of Merger (the Merger Agreement) with SmithKline Beecham
Corporation, a Pennsylvania corporation (SKB), and Fountain Acquisition Corporation,
a Delaware corporation and a wholly-owned subsidiary of SKB (the Purchaser),
pursuant to which, among other things, the Purchaser has agreed to commence a
tender offer (the Offer) for all the outstanding shares of common stock of
Sirtris at a purchase price of $22.50 per share, subject to the terms and
conditions of the Merger Agreement. Provided that the tender offer results in
SKB acquiring at least a majority of the outstanding shares of Sirtriss common
stock, the consummation of the Offer will be followed by the merger of the
Purchaser with and into Sirtris (the Merger), with Sirtris surviving as an
indirect wholly-owned subsidiary of SKB and GlaxoSmithKline plc (GSK).
The named executive officers have entered into letter
agreements with GSK (the Letter
Agreements) and Dr. David Sinclair entered into a Research Advisory and
Consulting Agreement with GSK (the Research and Consulting Agreement), which
are effective and contingent upon the consummation of the Merger. The Letter Agreements
and Research and Consulting Agreement will include details regarding salary and
bonus, stock options, stock awards and health and welfare benefits. Further
information relating to the compensation of the named executive officers and
Dr. David Sinclair in connection with the Merger will be disclosed in the
Companys Schedule 14D-9 to be filed in connection with the tender offer.
Conclusion
Our compensation policies are designed to retain and
motivate our executive officers and to ultimately reward them for outstanding
individual and corporate performance.
REPORT OF THE COMPENSATION COMMITTEE
The Compensation Committee of our Board of Directors
has reviewed and discussed the compensation discussion and analysis required by
Item 402(b) of Regulation S-K with our management. Based on this review
and discussion, the Compensation Committee has recommended to the Board of
Directors that the compensation discussion and analysis be included in our Annual
Report on Form 10-K/A.
COMPENSATION COMMITTEE
Stephen Hoffman
Paul Friedman
Richard Aldrich
EXECUTIVE COMPENSATION
Summary
Compensation Table
The following table shows the compensation paid or
accrued during the fiscal year ended December 31, 2007 to (1) our
Chief Executive Officer, (2) our Chief Operating Officer and (3) our
two most highly compensated executive officers, other than our President and
Chief Executive Officer and our Chief Operating Officer.
Name and Principal
Position
|
|
Year
|
|
Salary($)
|
|
Stock
awards($)(1)
|
|
Options
awards($)(2)
|
|
Non-Equity
incentive
plan compensation ($)
|
|
All other
compensation($)
|
|
Total($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Christoph Westphal,
|
|
2007
|
|
$
|
389,340
|
|
$
|
24,361
|
(3)
|
$
|
159,307
|
(5)
|
$
|
183,800
|
(13)
|
$
|
9,900
|
(16)
|
$
|
766,708
|
|
M.D., Ph.D.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
President and Chief Executive
|
|
2006
|
|
$
|
378,000
|
|
$
|
30,350
|
(4)
|
$
|
57,035
|
(6)
|
$
|
103,950
|
(14)
|
$
|
7,650
|
(17)
|
$
|
576,985
|
|
Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Garen Bohlin
|
|
2007
|
|
$
|
298,700
|
|
|
|
$
|
143,679
|
(7)
|
$
|
93,100
|
(13)
|
$
|
9,900
|
(18)
|
$
|
545,379
|
|
Chief Operating
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Officer
|
|
2006
|
|
$
|
290,000
|
|
|
|
$
|
107,177
|
(8)
|
$
|
58,000
|
(14)
|
$
|
9,903
|
(19)
|
$
|
465,080
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Peter Elliott, Ph.D.
|
|
2007
|
|
$
|
297,413
|
|
|
|
$
|
28,627
|
(9)
|
$
|
92,800
|
(13)
|
$
|
6,848
|
(20)
|
$
|
425,688
|
|
Senior Vice President,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Head of Development
|
|
2006
|
|
$
|
288,750
|
|
|
|
$
|
13,494
|
(10)
|
$
|
77,750
|
(14)
|
$
|
6,957
|
(21)
|
$
|
386,951
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Michael Jirousek,
|
|
2007
|
|
$
|
263,120
|
|
|
|
$
|
135,605
|
(11)
|
$
|
82,200
|
(13)
|
$
|
9,289
|
(22)
|
$
|
490,214
|
|
Ph.D.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Senior Vice President, Research
|
|
2006
|
|
$
|
86,667
|
|
|
|
$
|
24,706
|
(12)
|
$
|
140,000
|
(15)
|
$
|
19,737
|
(23)
|
$
|
271,110
|
|
10
(1)
Amount
reflects the compensation cost for the year ended December 31, 2007 of the
named executive officers awards of restricted common stock, calculated in
accordance with SFAS 123(R). For purposes of this calculation, we have
disregarded the estimate of forfeitures related to service-based vesting
conditions. There can be no assurance that the SFAS 123(R) amounts will
ever be realized by the executive. See notes 2 of Notes to Consolidated
Financial Statements in our Annual Report on Form 10-K filed with the SEC
on March 24, 2008 for a discussion of assumptions made by the Company in
determining the grant date fair value and compensation costs of our equity
awards.
(2) Amount reflects
the compensation cost for the year ended December 31, 2007 of the named
executive officers stock options, calculated in accordance with SFAS 123(R) and
using a Black-Scholes valuation model for 2006 and 2007 awards, using SFAS 123
for 2005 awards and using APB No. 25 for awards prior to 2005. For
purposes of this calculation, we have disregarded the estimate of forfeitures
related to service-based vesting conditions. There can be no assurance that the
accounting compensation costs will ever be realized by the executive. See notes
2 of Notes to Consolidated Financial Statements in our Annual Report on Form 10-K
filed with the SEC on March 24, 2008 for a discussion of assumptions made
by the Company in determining the grant date fair value and compensation costs
of our stock option grants.
(3) Represents the
compensation expense incurred by us in fiscal year 2007 in connection with a
grant of 380,952 shares of restricted common stock to Dr. Westphal on February 10,
2005, calculated in accordance with Accounting Principles Board Opinion No. 25.
(4) Represents the
compensation expense incurred by us in fiscal year 2006 in connection with a
grant of 380,952 shares of restricted common stock to Dr. Westphal on February
10, 2005, calculated in accordance with Accounting Principles Board Opinion No.
25.
(5) Consists of
$5,075 and $154,232, representing the compensation expense in fiscal year 2007
in connection with option grants to Dr. Westphal to purchase 268,707
shares of common stock on July 27, 2005 and 355,219 shares of common stock
on August 30, 2006.
(6) Consists of $5,061
and $51,974, representing the compensation expense in fiscal year 2006 in
connection with option grants to Dr. Westphal to purchase 268,707 shares of common
stock on July 27, 2005 and 355,219 shares of common stock on August 30, 2006.
(7) Consists of
$116,290 and $27,389, representing the compensation expense in fiscal year 2007
in connection with option grants to Mr. Bohlin to purchase 285,714 shares
of common stock on February 28, 2006 and 42,858 shares of common stock on August 30,
2006.
(8) Consists of $97,493
and $9,685, representing the compensation expense in fiscal year 2006 in
connection with option grants to Mr. Bohlin to purchase 285,714 shares of
common stock on February 28, 2006 and 42,858 shares of common stock on August
30, 2006.
(9) Consists of
$4,883 and $23,744, representing the compensation expense in fiscal year 2007
in connection with option grants to Dr. Elliott to purchase 257,143 shares
of common stock on September 20, 2005 and 57,143 shares of common stock on
August 30, 2006.
(10) Consists of $5,493
and $8,001, representing the compensation expense in fiscal year 2006 in
connection with option grants to Dr. Elliott to purchase 257,143 shares of
common stock on September 20, 2005 and 57,143 shares of common stock on August
30, 2006.
(11) Consists of
$71,231, $16,007 and $48,367, representing the compensation expense in fiscal
year 2007 in connection with option grants to Dr. Jirousek to purchase
171,429 shares of common stock on August 30, 2006, 19,048 shares of common
stock on December 15, 2006 and 57,143 shares of common stock on February 12,
2007.
(12) Consists of $24,004
and $702, representing the compensation expense in fiscal year 2006 in
connection with option grants to Dr. Jirousek to purchase 171,429 shares of
common stock on August 30, 2006 and 19,048 shares of common stock on December
15, 2006.
(13) Bonus amounts
for performance during the fiscal year ended December 31, 2007 were
approved by the Board of Directors in January 2008 and were paid in January 2008.
(14) Bonus amounts for
performance during the fiscal year ended December 31, 2006 were approved by the
board of directors in December 2006 but were not paid until January 2007.
(15) Sign on bonus paid
during the fiscal year ended December 31, 2006.
(16) Represents $900
life and disability insurance premium
and $9,000 from our contribution to Dr. Westphals 401(k) plan.
(17) Represents $720
group term life insurance premium and $6,930 from our contribution to Dr.
Westphals 401(k) plan.
(18) Represents $900
life and disability insurance premium
and $9,000 from our contribution to Mr. Bohlins 401(k) plan.
(19) Represents $720
group term life insurance premium and $9,183 from our contribution to Mr.
Bohlins 401(k) plan.
(20) Represents $900 life
and disability insurance premium and $5,948 from our contribution to Dr. Elliotts
401(k) plan.
(21) Represents $720
group term life insurance premium and $6,237 from our contribution to Dr.
Elliotts 401(k) plan.
(22) Represents $518 life
and disability insurance premium and $8,771 from our contribution to Dr. Jirouseks
401(k) plan.
(23) Represents $720
group term life insurance premium, $12,000 in temporary housing allowance and
$7,017 in tax reimbursement for temporary housing allowance.
11
Grants
of Plan-Based Awards
The
following table shows information regarding grants of equity awards during the
fiscal year ended December 31, 2007 held by the executive officers named
in the Summary Compensation Table.
Name
|
|
Grant date
|
|
All other option awards:
number of securities
underlying
options granted (#)
|
|
Exercise price of
option awards
($/Share) (1)
|
|
Grant date fair
value of option
awards ($) (2)
|
|
|
|
|
|
|
|
|
|
|
|
Christoph
Westphal, M.D., Ph.D.
President and Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Garen Bohlin
Chief Operating Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Peter Elliott,
Ph.D.
Senior Vice President,
Head of Development
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Michael
Jirousek, Ph.D.
Senior Vice President, Research
|
|
2/13/07
|
|
57,143
|
|
$
|
5.99
|
|
$
|
226,401
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) The exercise
price of the option award is the closing market value of our common stock as
reported on the NASDAQ Global Market on the date of the grant.
(2) The grant date
fair value was calculated using the Black-Scholes option pricing model. In
making this calculation, we used the assumptions described in Note 2 Summary
of Significant Accounting Policies Stock-Based Compensation of the Notes to
the Consolidated Financial Statements included as part of our Annual Report on Form 10-K
filed with the SEC on March 24, 2008 for the fiscal year ended December 31,
2007, excluding assumptions related to forfeitures.
Fiscal
Year 2007 Equity Awards
All of the stock option awards disclosed in the Grants
of Plan-Based Awards Table were issued under our Plan. All options granted
prior to May 23, 2007 were granted with an exercise price per share equal
to the fair market value of our common stock on the date of grant, as
determined by our Board of Directors. All stock option awards granted on or
after May 23, 2007 were granted with an exercise price equal to the
closing market value of our common stock as reported on the NASDAQ Global
Market on the date of the grant. Subject
to the terms of the Plan and the option agreements issued in connection with
these grants, all of these options granted to our executive officers in 2007
vest as to 25% of the shares on the first anniversary of the grant date and as
to an additional 6.25% of the shares on each quarterly anniversary thereafter.
The vesting conditions for each of the executive officers stock option grants
include an alternate vesting schedule following a change of control (see Compensation
Discussion and AnalysisTermination Based CompensationAcceleration of vesting
of equity-based awards).
Employment
Agreements
We have entered into employment agreements with each
of Christoph Westphal, M.D., Ph.D., our President and Chief Executive Officer,
Garen Bohlin, our Chief Operating Officer, Peter Elliott, Ph.D., our Senior
Vice President, Head of Development and Michael Jirousek, Ph.D., our Senior
Vice President, Research. Termination for cause is defined in each of these
employment agreements as: (i) the executives willful failure to perform,
or gross negligence in the performance of, his duties and responsibilities to
the Company and its affiliates which is not remedied within thirty (30) days of
notice thereof; (ii) material breach by the executive of any material
provision of the employment agreement or any other agreement with the Company
or any of its affiliates which is not remedied within thirty (30) days of
notice thereof; (iii) fraud, embezzlement or other dishonesty with respect
to the Company and any of its affiliates, taken as a whole, which, in the case
of such other dishonesty, causes or could reasonably be expected to cause
material harm to the Company and any of its affiliates, taken as a whole; or (iv) his
conviction of a felony.
If the executives are terminated for Cause or
terminate their employment without Good Reason (as defined in their respective
employment agreements), the Companys only obligation would be to pay any
unpaid salary and/or bonus and any vacation time accrued but not used as of the
date of termination. In this case the
Company would also have the right to repurchase any unvested restricted shares
from Dr. Westphal at a price of $0.001 per share. A change of control is defined in each of
these employment agreements as: (i) the acquisition of beneficial
ownership (as defined in Rule 13d-3 under the Exchange Act) directly or
indirectly by any person (as such term is used in Sections 13(d) and 14(d) of
the Exchange Act), of securities of the Company representing a majority or more
of the combined voting power of the Companys then outstanding securities,
other than an acquisition of securities for investment purposes pursuant to a
bona fide financing of the Company; (ii) a merger or consolidation of the
Company with any other corporation in which the holders of the voting
securities of the Company prior to the merger or consolidation do not own more
than 50% of the total voting securities of the surviving
12
corporation; or (iii) the
sale or disposition by the Company of all or substantially all of the Companys
assets other than a sale or disposition of assets to an affiliate of the
Company or a holder of securities of the Company.
Christoph Westphal, M.D., Ph.D., President and Chief
Executive Officer
Under Dr. Westphals amended and restated
employment agreement, dated January 3, 2008, he serves as our President
and Chief Executive Officer. The Company also agreed that so long as Dr. Westphal
continues to serve as our President and Chief Executive Officer, he will be
nominated by the Board of Directors for election as a director at each annual
meeting preceding which his term as director expires. Dr. Westphals
current base salary is $450,000. This amount is subject to adjustment from time
to time at the discretion of the Board of Directors or the Compensation
Committee. As a condition of employment, Dr. Westphal entered into a
non-competition/non-solicitation agreement pursuant to which he has agreed not
to compete with Sirtris or to solicit customers or employees of Sirtris for a
period of 12 months after the termination of his employment. If Dr. Westphals
employment is terminated without cause, he terminates his employment for good
reason, he becomes permanently disabled, or upon his death, he will receive the
following severance benefits following his employment termination: (a) base
salary for a period of 12 months and a pro rata portion (for the period from January 1
of that year to the date of termination) of the target cash bonus for the year
in which he is terminated; (b) vesting in 12 months worth of his then
unvested options and restricted stock which, by their terms, vest only based on
the passage of time (disregarding any acceleration of the vesting of such
options based on individual or Company performance); and (c) the premium
cost of participation in our medical and/or dental plans for 12 months, subject
to applicable law and plan terms.
In addition, upon consummation of a change of control,
Dr. Westphal would become vested in 100% of his then unvested options and
restricted stock which, by their terms, vest only based on the passage of time
(disregarding any acceleration of the vesting of such options based on individual
or Company performance). If, within one year following a change of control, Dr. Westphal
is terminated without cause or he terminates his employment for good reason, he
will receive a lump sum payment equal to the his then-current annual base
salary for a period of 18 months and a pro-rata portion (for the period from January 1
of the year of termination through the date of termination) of the target cash
bonus for the year in which he is terminated. Dr. Westphal will only be
eligible to receive severance payments if he signs a general release of claims.
Dr. Westphal may also be entitled to an additional tax gross-up payment
for any excise tax imposed on excess parachute payments under Section 4999
of the Internal Revenue Code.
Under Dr. Westphals employment agreement,
good reason
is defined as: (i) material
diminution in the nature or scope of his responsibilities, duties or authority,
provided that in the absence of a Change of Control neither of the following
shall constitute Good Reason: (x) the Companys failure to continue his
appointment or election as a director or officer of any of its affiliates or (y) any
diminution in the nature or scope of his responsibilities, duties or authority
that is reasonably related to a diminution of the business of the Company or
any of its affiliates; (ii) any diminution in position, base salary or
bonus or in the nature or scope of his responsibilities, duties or authority
in anticipation of or after a Change of
Control, it being specifically acknowledged that his failure to continue as
Chief Executive Officer of the Company and to serve on the Board of Directors
of the Company (and any parent company directly or indirectly owning or
controlling 50% or more of the securities of the Company after the Change of
Control) shall constitute good reason;
(iii) a reduction in his base salary other than one temporary reduction of
not more than 120 days and not in excess of 20% of the his base salary in
connection with and in proportion to a general reduction of the base salaries
of the Companys executive officers; (iv) failure of the Company to
provide him the salary or benefits in accordance with the employment agreement
after thirty (30) days notice during which the Company does not cure such
failure; or (v) relocation of his office more than thirty-five (35) miles
from the location of the Companys principal offices as of January 1,
2008.
Garen Bohlin, Chief Operating Officer
Under Mr. Bohlins amended and restated
employment agreement, dated January 3, 2008, he serves as our Chief
Operating Officer. Mr. Bohlins current annual base salary is $330,000.
This amount is subject to adjustment from time to time at the discretion of the
Board of Directors or the Compensation Committee. As a condition of employment,
Mr. Bohlin has entered into a non-competition/non-solicitation agreement
pursuant to which he has agreed not to compete with Sirtris or to solicit
customers or employees of Sirtris for a period of 18 months after the
termination of his employment. If Mr. Bohlins employment is terminated
without cause, he terminates his employment for good reason, he becomes
permanently disabled, or upon his death, he will receive the following
severance benefits following his employment termination: (a) base salary
for a period of 12 months and a pro rata portion (for the period from January 1
of that year to the date of termination) of the target cash bonus for the year
in which he is terminated; (b) vesting in 12 months worth of his then
unvested options and restricted stock which, by their terms, vest only based on
the passage of time (disregarding any
13
acceleration of the vesting of such options based on individual or
Company performance); and (c) the premium cost of participation in our
medical and/or dental plans for 12 months, subject to applicable law and plan
terms.
In addition, upon the consummation of a change of
control, Mr. Bohlin would become vested in 25% of his then unvested
options and restricted stock which, by their terms, vest only based on the
passage of time (disregarding any acceleration of the vesting of such options
based on individual or Company performance). If, within one year following or
in connection with a change of control, Mr. Bohlin is terminated without
cause or he terminates his employment for good reason, he will receive (i) a
lump sum payment equal to 12 months of the then current base salary and a
pro-rata portion (for the period of January 1 through the date of
termination) of the target cash bonus paid for the year in which he is
terminated and (ii) vesting of the remainder of his unvested options and
restricted stock (taking into account the amount he received upon the
consummation of the change of control). Mr. Bohlin will only be eligible
to receive severance payments if he signs a general release of claims. Mr. Bohlin
may also be entitled to an additional tax gross-up payment for any excise tax
imposed on excess parachute payments under Section 4999 of the Internal
Revenue Code.
Under Mr. Bohlins employment agreement,
good reason
is defined as (i) material
diminution in the nature or scope of his responsibilities, duties or authority,
provided that in the absence of a Change of Control neither of the following
shall constitute Good Reason: (x) the Companys failure to continue his
appointment or election as a director or officer of any of its affiliates nor (y) any
diminution in the nature or scope of his responsibilities, duties or authority
that is reasonably related to a diminution of the business of the Company or
any of its affiliates; (ii) a reduction in his base salary other than one
temporary reduction of not more than 120 days and not in excess of 20% of his
base salary in connection with and in proportion to a general reduction of the
base salaries of the Companys executive officers; (iii) failure of the
Company to provide him the salary or benefits in accordance with the employment
agreement after thirty (30) days notice during which the Company does not cure
such failure; or (iv) relocation of his office more than thirty-five (35)
miles from the location of the Companys principal offices as January 1,
2008.
Peter Elliott, Ph.D., Senior Vice President, Head of
Development
Under Dr. Elliotts amended and restated employment
agreement, dated January 3, 2008, he serves as our Senior Vice President,
Head of Development. Dr. Elliotts current annual base salary is $322,500.
This amount is subject to adjustment from time to time at the discretion of the
Board of Directors or the Compensation Committee. As a condition of employment,
Dr. Elliott has entered into a non-competition/non-solicitation agreement
pursuant to which he has agreed not to compete with Sirtris or to solicit
customers or employees of Sirtris for a period of 18 months after the
termination of his employment. If Dr. Elliotts employment is terminated
without cause, he terminates his employment for good reason, he becomes
permanently disabled, or upon his death, he will receive the following
severance benefits following his employment termination: (a) base salary
for a period of 12 months and a pro rata portion (for the period from January 1
of that year to the date of termination) of the target cash bonus for the year
in which he is terminated; (b) vesting in 12 months worth of his then
unvested options and restricted stock which, by their terms, vest only based on
the passage of time (disregarding any acceleration of the vesting of such
options based on individual or Company performance); and (c) the premium
cost of participation in our medical and/or dental plans for 12 months, subject
to applicable law and plan terms.
In addition, upon the consummation of a change of
control, Dr. Elliott would become vested in 25% of his then unvested
options and restricted stock which, by their terms, vest only based on the
passage of time (disregarding any acceleration of the vesting of such options
based on individual or Company performance). If, within one year following or
in connection with a change of control, Dr. Elliott is terminated without
cause or he terminates his employment for good reason, he will receive (i) a
lump sum payment equal to 12 months of the then current base salary and a
pro-rata portion (for the period of January 1 through the date of
termination) of the target cash bonus for the year in which he is terminated
and (ii) vesting of the remainder of his then remaining unvested options
and restricted stock (taking into account the amount he received upon the
consummation of the change of control). Dr. Elliott will only be eligible
to receive severance payments if he signs a general release of claims. Dr. Elliott
may also be entitled to an additional tax gross-up payment for any excise tax
imposed on excess parachute payments under Section 4999 of the Internal
Revenue Code.
14
Under Dr. Elliotts employment agreement,
good reason
is defined as (i) material
diminution in the nature or scope of his responsibilities, duties or authority,
provided that in the absence of a Change of Control none of the following shall
constitute Good Reason: (x) the Companys failure to continue his
appointment or election as a director or officer of any of its affiliates; (y) any
diminution in the nature or scope of his responsibilities, duties or authority
that is reasonably related to a diminution of the business of the Company or
any of its affiliates; or (z) the hiring of a head of Research and
Development for the Company other than the executive and any resultant change
in his responsibilities, duties or authority reasonably related to such hire; (ii) a
reduction in his base salary other than one temporary reduction of not more
than 120 days and not in excess of 20% of his base salary in connection with
and in proportion to a general reduction of the base salaries of the Companys
executive officers; (iii) failure of the Company to provide the executive
the salary or benefits in accordance with the employment agreement after thirty
(30) days notice during which the Company does not cure such failure or (iv) relocation
of his office more than thirty-five (35) miles from the location of the Companys
principal offices as of January 1, 2008.
Michael Jirousek, Ph.D., Senior Vice President, Research
Under Dr. Jirouseks amended and restated
employment agreement, dated January 3, 2008, he serves as our Senior Vice
President, Research. Dr. Jirouseks current annual base salary is
$290,000. This amount is subject to adjustment from time to time at the
discretion of the Board of Directors or the Compensation Committee. As a
condition of employment, Dr. Jirousek has entered into a
non-competition/non-solicitation agreement pursuant to which he has agreed not
to compete with Sirtris or to solicit customers or employees of Sirtris for a
period of 18 months after the termination of his employment. If Dr. Jirouseks
employment is terminated without cause, he terminates his employment for good
reason, he becomes permanently disabled, or upon his death, he will receive the
following severance benefits following his employment termination: (a) base
salary for a period of 12 months and a pro rata portion (for the period from January 1
of that year to the date of termination) of the target cash bonus for the year
in which he is terminated; (b) vesting in 12 months worth of his then
unvested options and restricted stock which, by their terms, vest only based on
the passage of time (disregarding any acceleration of the vesting of such
options based on individual or Company performance); and (c) the premium
cost of participation in our medical and/or dental plans for 12 months, subject
to applicable law and plan terms.
In addition, upon the consummation of a change of
control, Dr. Jirousek would become vested in 25% of his then unvested
options and restricted stock which, by their terms, vest only based on the
passage of time (disregarding any acceleration of the vesting of such options
based on individual or Company performance). If, within one year following or
in connection with a change of control, Dr. Jirousek is terminated without
cause or he terminates his employment for good reason, he will receive (i) a
lump sum payment equal to 12 months of the then current base salary and a
pro-rata portion (for the period of January 1 through the date of
termination) of the target cash bonus for the year in which he is terminated
and (ii) vesting of the remainder of his then remaining unvested options
and restricted stock (taking into account the amount he received upon the
consummation of the change of control). Dr. Jirousek will only be eligible
to receive severance payments if he signs a general release of claims. Dr. Jirousek
may also be entitled to an additional tax gross-up payment for any excise tax
imposed on excess parachute payments under Section 4999 of the Internal
Revenue Code.
Under Dr. Jirouseks employment agreement,
good reason
is defined as (i) material
diminution in the nature or scope of his responsibilities, duties or authority,
provided that neither of the following shall constitute Good Reason: (x) the
Companys failure to continue his appointment or election as a director or
officer of any of its affiliates nor (y) any diminution in the nature or
scope of his responsibilities, duties or authority that is reasonably related
to a diminution of the business of the Company or any of its affiliates, other
than any such diminution resulting from the sale or transfer of any or all of
the assets of the Company or any of its affiliates;
(ii) a reduction in his base salary other than one
temporary reduction of not more than 120 days and not in excess of 20% of his
base salary in connection with and in proportion to a general reduction of the
base salaries of the Companys executive officers; (iii) failure of the
Company to provide the executive the salary or benefits in accordance with the
employment agreement after thirty (30) days notice during which the Company
does not cure such failure; or (iv) relocation of his office more than
thirty-five (35) miles from the location of the Companys principal offices as
of January 1, 2008.
Compensation
Elements of the Proposed SKB Transaction
GSK entered into separate Letter Agreements with the
named executive officers and a Research and Consulting Agreement with Dr. David
Sinclair. The Letter Agreements, which are effective and contingent upon the
consummation of the Merger, contain terms relating to the employment of the
executive officers following the effective time of the Merger. The Research and
Consulting Agreement, which is effective and contingent upon the consummation
of the Merger, contain terms regarding Dr. Sinclairs compensation following
the effective time of the Merger. Further information relating to the
compensation of the named executive officers and Dr. David Sinclair in connection
with the Merger will be disclosed in the Companys Schedule 14D-9 to be
filed in connection with the tender offer.
Severance
and Change in Control Arrangements
See Employment Agreements above for a description of
the severance and change in control arrangements for Drs. Westphal,
Elliott and Jirousek and Mr. Bohlin.
15
The Compensation Committee of our Board of Directors,
as plan administrator of our Amended and Restated 2004 Incentive Plan, may provide
for the assumption or substitution of some or all outstanding awards by the
acquiror or survivor in the event of a covered transaction, in which there is
an acquiring or surviving entity. In the absence of an assumption or
substitution, each stock option will become fully exercisable prior to the
covered transaction on a basis that gives the holder of the stock option a
reasonable opportunity as determined by the Compensation Committee, to
participate as a stockholder in the covered transaction following exercise, and
the stock option will terminate upon consummation of the covered transaction.
In the case of restricted stock, the Compensation Committee may require that
any amounts delivered, exchanged or otherwise paid in respect of such stock in
connection with the covered transaction be placed in escrow or otherwise made
subject to such restrictions as the Board of Directors deems appropriate.
Immediately upon termination of employment of an
employee, the unvested portion of any stock option will terminate and the
balance, to the extent exercisable, will remain exercisable for the lesser of (i) a
period of three months or (ii) the period ending on the latest date on
which such stock option could have been exercised without regard to this
provision. The plan provides exceptions for the vesting of options upon an
individuals death or if the Compensation Committee determines that the
termination of employment resulted for reasons that cast discredit on the
individual.
Potential
Payments and Benefits Upon Termination and Change in Control
The following tables present estimates of the amounts
that would have been payable to each named executive officer under our new
employment agreements upon the occurrence of certain triggering events as of
the end of our last fiscal year ended December 31, 2007 (assuming the new
agreements, each dated January 3, 2008, had been in effect on such date). The closing price of the Companys stock on
the NASDAQ Global Market as of December 31, 2007, was $13.69, which was
used as the value of the Companys stock in the change in control. The value of
the option vesting acceleration was calculated by multiplying the number of
unvested option shares subject to vesting acceleration as of December 31,
2007 by the difference between the closing price of the Companys stock as of December 31,
2007 and the exercise price for such unvested option shares. The value of the
restricted stock vesting acceleration was calculated by multiplying the number
of unvested shares of restricted stock subject to vesting acceleration as of December 31,
2007 by the closing price of the Companys stock as of December 31, 2007.
Christoph Westphal, M.D., Ph.D., President and Chief
Executive Officer
The following table describes the potential payments
and benefits upon employment termination for Christoph Westphal, our President
and Chief Executive Officer, as if his employment terminated as of December 31,
2007, the last business day of our last fiscal year (assuming his new
employment agreement, dated January 3, 2008, was in effect on such date).
|
|
Termination
|
|
|
|
Termination not
|
|
|
|
not for
|
|
|
|
for cause or
|
|
|
|
cause,
|
|
|
|
resignation for
|
|
|
|
resignation
|
|
Upon
|
|
good reason in
|
|
|
|
for good
|
|
consummation
|
|
connection with
|
|
|
|
reason,
|
|
of a
|
|
or following a
|
|
|
|
death or
|
|
change in
|
|
change
|
|
|
|
disability
|
|
control
|
|
of control
|
|
Base salary and
Bonus
|
|
$
|
720,000
|
(1)
|
$
|
|
|
$
|
945,000
|
(7)
|
Benefits
|
|
$
|
33,589
|
(2)
|
$
|
|
|
$
|
33,589
|
(2)
|
Number of Stock
Options
|
|
143,421
|
(3)
|
393,175
|
(5)
|
|
|
Value
|
|
$
|
1,851,351
|
|
$
|
5,030,014
|
|
$
|
|
|
Number of Shares
of Vested Stock Received
|
|
76,190
|
(4)
|
76,190
|
(6)
|
|
|
Value
|
|
$
|
1,042,279
|
|
$
|
1,042,279
|
|
$
|
|
|
Tax Gross Up
Payment
|
|
|
|
|
|
727,790
|
(8)
|
Total
|
|
$
|
3,647,219
|
|
$
|
6,072,293
|
|
$
|
1,706,379
|
|
(1) Last monthly base
salary prior to the termination for a period of 12 months following the date of
termination plus the pro rata portion of his bonus from the period of January
1, 2007 to December 31, 2007.
16
(2) Payment of premium
cost of participation in our health and/or dental insurance plans for 12 months
and 10 vacation days available to Dr. Westphal at December 31, 2007.
(3) Acceleration of 12
months worth of Dr. Westphals then unvested options.
(4) Acceleration of 12
months worth of Dr. Westphals then unvested restricted stock.
(5) Acceleration of 100%
of Dr. Westphals then unvested options.
(6) Acceleration of 100%
of Dr. Wespthals then unvested restricted stock.
(7) Last monthly base
salary prior to the termination for a period of 18 months following the date of
termination plus the pro rata portion of his bonus from the period of January
1, 2007 to December 31, 2007.
(8) The estimated
gross-up amount shown above reflects the terms of the employment agreement
entered into between Christoph Westphal and the Company, dated January 3, 2008
but is otherwise based on relevant entitlements in effect on December 31, 2007
and assumes a cash-out of Dr. Westphals equity awards in the change in
control.
Garen Bohlin, Chief Operating Officer
The following table describes the potential payments
and benefits upon employment termination for Garen Bohlin, the Companys Chief
Operating Officer, as if his employment terminated as of December 31,
2007, the last business day of our last fiscal year (assuming his new
employment agreement, dated January 3, 2008, was in effect on such date).
|
|
|
|
|
|
Termination not for cause or
|
|
|
|
Termination not for
|
|
|
|
resignation for good reason
|
|
|
|
cause, resignation
|
|
Upon consummation
|
|
in connection with
|
|
|
|
for good reason, death or
|
|
of a change
|
|
or following a change
|
|
|
|
disability
|
|
in control
|
|
of control
|
|
Base salary and
Bonus
|
|
$
|
462,000
|
(1)
|
$
|
|
|
$
|
462,000
|
(1)
|
Benefits
|
|
$
|
20,949
|
(2)
|
$
|
|
|
$
|
20,949
|
(2)
|
Number of Stock
Options
|
|
82,144
|
(3)
|
47,546
|
(4)
|
190,181
|
(5)
|
Value
|
|
$
|
1,056,336
|
|
$
|
611,060
|
|
$
|
2,444,200
|
|
Tax Gross Up
Payment
|
|
|
|
|
|
291,366
|
(6)
|
Total
|
|
$
|
1,539,285
|
|
$
|
611,060
|
|
$
|
3,218,515
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Last monthly
base salary prior to the termination for a period of 12 months following the
date of termination plus the pro rata portion of his bonus from the period of January 1,
2007 to December 31, 2007.
(2) Payment of
premium cost of participation in our health and/or dental insurance plans for
12 months and 8 vacation days available to Mr. Bohlin at December 31,
2007.
(3) Acceleration of
12 months worth of Mr. Bohlins then unvested options.
(4) Acceleration of 25%
of Mr. Bohlins then unvested options.
(5) Acceleration of 100%
of Mr. Bohlins then unvested options.
(6) The estimated
gross-up amount shown above reflects the terms of the employment agreement
entered into between Garen Bohlin and the Company, dated January 3, 2008 but is
otherwise based on relevant entitlements in effect on December 31, 2007 and
assumes a cash-out of Mr. Bohlins equity awards in the change in control.
Peter Elliott, Ph.D., Senior Vice President, Head of
Development
The following table describes the potential payments
and benefits upon employment termination for Peter Elliott, the Companys
Senior Vice President, Head of Development, as if his employment terminated as
of December 31, 2007, the last business day of our last fiscal year
(assuming his new employment agreement, dated January 3, 2008, was in effect on
such date).
17
|
|
|
|
|
|
Termination not for cause or
|
|
|
|
Termination not for
|
|
|
|
resignation for good reason
|
|
|
|
cause, resignation
|
|
|
|
in connection with
|
|
|
|
for good reason, death or
|
|
Upon consummation of
|
|
or following a change
|
|
|
|
disability
|
|
a change in control
|
|
of control
|
|
Base salary and
Bonus
|
|
$
|
435,375
|
(1)
|
$
|
|
|
$
|
435,375
|
(1)
|
Benefits
|
|
$
|
24,013
|
(2)
|
$
|
|
|
$
|
24,013
|
(2)
|
Number of Stock
Options
|
|
73,810
|
(3)
|
35,864
|
(4)
|
143,454
|
(5)
|
Value
|
|
$
|
969,744
|
|
$
|
469,236
|
|
$
|
1,876,919
|
|
Total
|
|
$
|
1,429,132
|
|
$
|
469,236
|
|
$
|
2,336,307
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Last monthly
base salary prior to the termination for a period of 12 months following the
date of termination plus the pro rata portion of his bonus from the period of January 1,
2007 to December 31, 2007.
(2) Payment of
premium cost of participation in our health and/or dental insurance plans for
12 months and 10 vacation days available to Dr. Elliott at December 31,
2007.
(3) Acceleration of
12 months worth of Dr. Elliotts then unvested options.
(4) Acceleration of 25%
of Dr. Elliotts then unvested
options.
(5) Acceleration of 100%
of Dr. Elliotts then unvested options.
Michael Jirousek, Ph.D., Senior Vice President, Research
The following table describes the potential payments
and benefits upon employment termination for Michael Jirousek, the Companys
Senior Vice President, Research, as if his employment terminated as of December 31,
2007, the last business day of our last fiscal year (assuming his new
employment agreement, dated January 3, 2008, was in effect on such date).
|
|
|
|
|
|
Termination not for cause or
|
|
|
|
Termination not for
|
|
|
|
resignation for good reason
|
|
|
|
cause, resignation
|
|
|
|
in connection with
|
|
|
|
for good reason, death or
|
|
Upon consummation of
|
|
or following a change
|
|
|
|
disability
|
|
a change in control
|
|
of control
|
|
Base salary and
Bonus
|
|
$
|
391,500
|
(1)
|
$
|
|
|
$
|
391,500
|
(1)
|
Benefits
|
|
$
|
21,266
|
(2)
|
$
|
|
|
$
|
21,266
|
(2)
|
Number of Stock
Options
|
|
72,618
|
(3)
|
47,323
|
(4)
|
189,287
|
(5)
|
Value
|
|
$
|
782,253
|
|
$
|
518,615
|
|
$
|
2,074,408
|
|
Total
|
|
$
|
1,195,019
|
|
$
|
518,615
|
|
$
|
2,487,174
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Last monthly
base salary prior to the termination for a period of 12 months following the
date of termination plus the pro rata portion of his bonus from the period of January 1,
2007 to December 31, 2007.
(2) Payment of
premium cost of participation in our health and/or dental insurance plans for
12 months and 17 vacation days available to Dr. Jirousek at December 31,
2007.
(3) Acceleration of
12 months worth of Dr. Jirouseks then unvested options.
(4) Acceleration of 25%
of Dr. Jirouseks then unvested options.
(5) Acceleration of 100%
of Dr. Jirouseks then unvested options.
Outstanding
Equity Awards at Fiscal Year-End
The following table shows grants of stock options and
grants of unvested stock awards outstanding on December 31, 2007, the last
day of our fiscal year, to each of the executive officers named in the Summary
Compensation Table.
18
|
|
Option awards
|
|
Stock awards
|
|
|
|
Number of
|
|
Number of
|
|
|
|
|
|
|
|
|
|
|
|
securities
|
|
securities
|
|
|
|
|
|
Number of
|
|
Market value
|
|
|
|
underlying
|
|
underlying
|
|
|
|
|
|
shares or
|
|
of shares of
|
|
|
|
unexercised
|
|
unexercised
|
|
Exercise
|
|
|
|
units of stock
|
|
units that
|
|
|
|
options (#)
|
|
options (#)
|
|
price
|
|
Expiration
|
|
that have not
|
|
have not
|
|
Name
|
|
exercisable
|
|
unexercisable
|
|
($/Share)
|
|
date
|
|
vested (#)
|
|
vested ($)(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Christoph Westphal,
M.D., Ph.D.
|
|
67,176
|
|
117,560
|
(2)
|
$
|
0.42
|
|
7/15/2015
|
|
76,190
|
(11)
|
1,043,041
|
|
President and Chief Executive Officer
|
|
79,604
|
|
275,615
|
(3)
|
$
|
1.10
|
|
8/30/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Garen Bohlin,
|
|
124,999
|
|
160,715
|
(4)
|
$
|
0.79
|
|
2/28/2016
|
|
|
|
|
|
Chief Operating
Officer
|
|
13,392
|
|
29,466
|
(5)
|
$
|
1.10
|
|
8/30/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Peter Elliott,
Ph.D.,
|
|
59,523
|
|
104,167
|
(6)
|
$
|
0.42
|
|
9/20/2015
|
|
|
|
|
|
Senior Vice
President,
|
|
17,856
|
|
39,287
|
(7)
|
$
|
1.10
|
|
8/30/2016
|
|
|
|
|
|
Head of
Development
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Michael
Jirousek, Ph.D.,
|
|
53,571
|
|
117,858
|
(8)
|
$
|
1.10
|
|
8/30/2016
|
|
|
|
|
|
Senior Vice
President,
|
|
4,762
|
|
14,286
|
(9)
|
$
|
3.15
|
|
12/15/2016
|
|
|
|
|
|
Research
|
|
|
|
57,143
|
(10)
|
$
|
5.99
|
|
2/13/2017
|
|
|
|
|
|
(1) The market value
of the stock award is determined by multiplying the number of shares times
$13.69, the closing price of our common stock on December 31, 2007.
(2) The option vests
as to 25% of the shares on July 27, 2006 and as to an additional 6.25% of
the shares on each of the next 12 quarterly anniversary dates thereafter.
(3) The option vests
as to 17.93% of the shares on August 30, 2007, approximately 4.5% of the
shares on each of the next 4 quarterly anniversary dates thereafter until August 30,
2008, approximately 8% of the shares on each of the next 4 quarterly
anniversary dates thereafter until August 30, 2009, and approximately 8%
of the shares on each of the next 4 quarterly anniversary dates thereafter
until August 30, 2010.
(4) The option vests
as to 25% of the shares on January 1, 2007 and as to an additional 6.25%
of the shares on each of the next 12 quarterly anniversary dates thereafter.
(5) The option vests
as to 25% of the shares on August 30, 2007 and as to an additional 6.25%
of the shares on each of the next 12 quarterly anniversary dates thereafter.
(6) The option vests
as to 25% of the shares on September 20, 2006 and as to an additional
6.25% of the shares on each of the next 12 quarterly anniversary dates
thereafter.
(7) The option vests
as to 25% of the shares on August 30, 2007 and as to an additional 6.25%
of the shares on each of the next 12 quarterly anniversary dates thereafter.
(8) The option vests
as to 25% of the shares on August 30, 2007 and as to an additional 6.25%
of the shares on each of the next 12 quarterly anniversary dates thereafter.
(9) The option vests
as to 25% of the shares on December 15, 2007 and as to an additional 6.25%
of the shares on each of the next 12 quarterly anniversary dates thereafter.
19
(10) The option
vests as to 25% of the shares on December 15, 2007 and as to an additional
6.25% of the shares on each of the next 12 quarterly anniversary dates thereafter.
(11) The stock award
vests as to 25% on February 13, 2008 and as to an additional 6.25% of the
shares on each of the next 12 quarterly anniversary dates thereafter.
Option
Exercises and Stock Vested
The following table presents certain information
concerning the exercise of options and the vesting of shares of restricted
stock held by named executive officers during the fiscal year ended December 31,
2007.
|
|
Option Awards
|
|
Stock Awards
|
|
Name
|
|
Number of Shares
Acquired on Exercise
(#)
|
|
Value Realized on
Exercise ($)
|
|
Number of Shares
Acquired on Vesting
(#)
|
|
Value Realized on
Vesting ($)
|
|
Christoph
Westphal, M.D., Ph.D.
President and Chief Executive Officer
|
|
83,971
|
|
885,054
|
|
76,190
|
|
1,043,041
|
|
Pension
Benefits
We do not have any qualified or non-qualified defined
benefit plans.
Nonqualified
Defined Contribution Plan
We do not have any nonqualified defined contribution
plans.
DIRECTOR COMPENSATION
We provide cash compensation to our directors for
their services as members of the Board of Directors and Board committees as
well as for attendance at Board of Directors or committee meetings. Also, our
directors are reimbursed for reasonable travel and other expenses incurred in
connection with attending meetings of the Board and its committees. Under our
Plan, directors are eligible to receive stock option grants at the discretion
of the Compensation Committee and restricted stock awards.
The following table sets forth a summary of the
compensation earned by our directors and/or paid to certain of our directors
pursuant to certain agreements we have with them in 2007, other than Dr. Westphal.
Name
|
|
Fees Earned
or Paid in
Cash ($)
|
|
Option Awards
($)(1)
|
|
All other
compensation
($)
|
|
Total ($)
|
|
Richard Aldrich
|
|
$
|
17,549
|
|
$
|
25,669
|
(5)
|
$
|
|
|
$
|
43,218
|
|
Jeffrey Capello
|
|
$
|
|
|
$
|
|
|
$
|
|
|
$
|
|
|
John Clarke
|
|
$
|
13,791
|
|
$
|
24,469
|
(6)
|
$
|
|
|
$
|
38,260
|
|
Alan Crane (1)
|
|
$
|
11,033
|
|
$
|
24,469
|
(6)
|
$
|
|
|
$
|
35,502
|
|
John Freund,
M.D. (2)
|
|
$
|
16,549
|
|
$
|
24,469
|
(6)
|
$
|
|
|
$
|
41,018
|
|
Stephen Hoffman,
Ph.D., M.D.
|
|
$
|
17,549
|
|
$
|
24,469
|
(6)
|
$
|
|
|
$
|
42,018
|
|
Wilfred Jaeger,
M.D. (3)
|
|
$
|
|
|
$
|
2,477
|
(7)
|
$
|
|
|
$
|
2,477
|
|
Stephen Kraus
(4)
|
|
$
|
|
|
$
|
2,477
|
(7)
|
$
|
|
|
$
|
2,477
|
|
Richard Pops
|
|
$
|
14,791
|
|
$
|
25,669
|
(8)
|
$
|
|
|
$
|
40,460
|
|
Paul Schimmel,
Ph.D.
|
|
$
|
25,291
|
|
$
|
24,862
|
(9)
|
$
|
|
|
$
|
50,153
|
|
David Sinclair,
Ph.D.
|
|
$
|
137,500
|
|
$
|
942,438
|
(10)
|
$
|
|
|
$
|
1,079,938
|
|
20
(1) Mr. Crane
resigned from our Board of Directors effective January 2, 2008.
(2) Dr. Freund
resigned from our Board of Directors effective January 2, 2008.
(3) Dr. Jaeger
resigned from our Board of Directors concurrently with the completion of our
initial public offering.
(4) Mr. Kraus
resigned from our Board of Directors concurrently with the completion of our
initial public offering.
(5) As of December 31,
2007, Mr. Aldrich held options to purchase an aggregate of 62,143 shares
of our common stock, 12,499 shares of which were vested as of December 31,
2007.
(6) As of December 31,
2007, Mr. Clarke, Dr. Freund and Dr. Hoffman each held options
to purchase an aggregate of 22,857 shares of our common stock, none of which
were vested as of December 31, 2007.
(7) As of December 31,
2007, Dr. Jaeger and Mr Kraus did not hold any options to purchase shares
of our common stock.
(8) As of December 31,
2007, Mr. Pops held options to purchase an aggregate of 89,524 shares of
our common stock, 39,880 shares of which were vested as of December 31,
2007.
(9) As of December 31,
2007, Dr. Schimmel held options to purchase an aggregate of 43,691 shares
of our common stock, no shares of which were vested as of December 31,
2007.
(10) As of December 31,
2007, Dr. Sinclair held options to purchase an aggregate of 920,907 shares
of our common stock, 451,542 shares of which were vested as of December 31,
2007.
Director
Compensation Policy
Upon completion of our initial public offering, we
instituted a Director Compensation Policy which outlines how members of the
Board of Directors are compensated for his or her services. Each non-employee
director received an option to purchase 22,857 shares of our common stock upon
his or her initial appointment to our Board of Directors. These options vest as
to one third of such grant on each of the first three anniversaries of the
grant date, subject to the non-employee directors continued service as a
director. Each non-employee director stock option will terminate on the earlier
of ten years from the date of grant and twelve months after the recipient
ceases to serve as a director. The exercise price of these options is equal to
the closing market value of our common stock as reported on the NASDAQ Global
Market on the date of the grant.
Under this policy each non-employee director is
compensated on an annual basis for providing services to us. Each non-employee
director receives cash compensation as follows:
·
$20,000
cash paid in quarterly installments;
·
$2,000
per Board meeting attended in person;
·
$600
per Board meeting attended telephonically;
·
$5,000
cash paid in quarterly installments for membership on the Compensation, Audit,
or Nominating and Governance Committee; and
·
$1,000
for each committee meeting attended.
In addition, each of these directors is eligible to
receive an annual grant of options to purchase 15,238 shares of common stock,
and these options will vest upon each directors re-election to the Board or
upon the conclusion of our annual meeting that follows the grant. The
chairperson of each of the Compensation Committee, Audit Committee and
Nominating and Governance Committee of the Board each received an additional
annual grant of options to purchase 5,714 shares of common stock, and, if the
Board appointed a Board chairperson or lead director, the director serving in
that capacity would receive an additional annual grant of options to purchase
7,619 shares of common stock.
21
Scientific
Advisory Board Arrangement with Dr. Paul Schimmel
We have an informal arrangement with Dr. Schimmel
pursuant to which Dr. Schimmel provides consulting services for 3/4th of a
day per month. We agreed to pay Dr. Schimmel $18,000 per year in monthly
installments of $1,500, for providing scientific advisory board services and to
reimburse his reasonable and necessary expenses incurred in performing services
for us. Dr. Schimmel was issued 76,191 shares of restricted stock in August 2004.
The vesting schedule is as follows: 25% of the shares on the date of issuance
and the remainder of the shares in equal installments over the next 48 months.
During 2007, Dr. Schimmel was paid $18,000 per this Scientific Advisory
Board Arrangement. The arrangement may be terminated by either party at any
time by giving notice to the other. Dr. Schimmel has not signed our
standard form of confidentiality, non-competition and proprietary information
agreement.
Consulting
Agreement with Dr. David Sinclair
In May 2004, we entered into a consulting
agreement with Dr. Sinclair pursuant to which Dr. Sinclair provides
consulting services for 20% of his time. Under the agreement, we agreed to pay Dr. Sinclair
$36,000 per year payable in monthly installments. Pursuant to the agreement, Dr. Sinclair
agreed not to provide consulting services or enter into consulting agreements
with any third parties without our prior written consent. In April 2005,
the agreement was amended to increase his compensation to $150,000 per year.
Under these agreements, Dr. Sinclair was paid $150,000 in 2007. The 2005
agreement had an initial term of one year and expired on February 28,
2006. It provided for extensions upon mutual agreement between him and us. In early
2006, both parties agreed to extend the agreement until February 28, 2007,
in early 2007, both parties agreed to extend the agreement until February 29,
2008 and in early 2008, both parties agreed to extend the agreement until February 28,
2009. This agreement may be terminated by either party at any time, with or
without cause, upon 60 days advance written notice to the other party. Dr. Sinclair
has signed our non-solicitation, non-disclosure and proprietary information
assignment agreement in which he has agreed not to compete with us or to
solicit our customers or employees for a period of 18 months after the
termination of his agreement.
Compensation
Committee Interlocks and Insider Participation
None of our executive officers serves as a member of
the Board of Directors or Compensation Committee, or other committee serving an
equivalent function, of any other entity that has one or more of its executive
officers serving as a member of our Board of Directors or Compensation Committee.
None of the current members of our Compensation Committee has ever been our
employee.
22
Item
12. Security Ownership of Certain
Beneficial Owners and Management and Related Stockholder Matters
The following sets forth information as of April 14,
2008 with respect to the beneficial ownership of our common stock, (i) by
each person known to us to own beneficially more than five percent of our
outstanding common stock, (ii) by each executive officer and each current
director, and (iii) by all officers and directors as a group.
Beneficial ownership is determined in accordance with
the rules of the Securities and Exchange Commission and includes voting or
investment power with respect to the securities. Shares of common stock that
may be acquired by an individual or group within 60 days of April 14,
2008, pursuant to the exercise of options or warrants, are deemed to be
outstanding for the purpose of computing the percentage ownership of such
individual or group, but are not deemed to be outstanding for the purpose of
computing the percentage ownership of any other person shown in the table. Percentage
of ownership is based on 29,265,413 shares of common stock outstanding on April 14,
2008.
Except as indicated in footnotes to this table, we
believe that the stockholders named in this table have sole voting and
investment power with respect to all shares of common stock shown to be
beneficially owned by them, based on information provided to us by such
stockholders.
Name and address of beneficial owner**
|
|
Number of shares
of common stock
beneficially owned
|
|
Percentage of
shares beneficially
owned
|
|
|
|
|
|
|
|
5%
Stockholders
|
|
|
|
|
|
FMR, L.L.C.(1)
|
|
3,730,925
|
|
12.8
|
%
|
John W. Henry
Trust dated July 20, 1990(2)
|
|
2,267,573
|
|
7.75
|
%
|
Funds managed by
Polaris(3)
|
|
2,245,342
|
|
7.67
|
%
|
CHP II, L.P.(4)
|
|
2,073,469
|
|
7.09
|
%
|
|
|
|
|
|
|
Directors
and Named Executive Officers
|
|
|
|
|
|
Christoph
Westphal, M.D., Ph.D.(5)
|
|
804,942
|
|
2.75
|
%
|
Garen Bohlin(6)
|
|
234,462
|
|
*
|
%
|
Peter Elliott,
Ph.D.(7)
|
|
253,070
|
|
*
|
%
|
Michael
Jirousek, Ph.D.(8)
|
|
94,307
|
|
*
|
%
|
Richard
Aldrich(9)
|
|
112,975
|
|
*
|
%
|
Jeffrey Capello
|
|
|
|
|
%
|
John Clarke(10)
|
|
2,081,088
|
|
7.11
|
%
|
Paul Friedman
|
|
|
|
|
%
|
Stephen Hoffman,
Ph.D., M.D. (11)
|
|
1,313,082
|
|
4.49
|
%
|
Richard Pops(12)
|
|
74,880
|
|
*
|
%
|
Paul Schimmel,
Ph.D.(13)
|
|
354,090
|
|
1.21
|
%
|
David Sinclair,
Ph.D.(14)
|
|
289,142
|
|
*
|
%
|
All current
executive officers and directors as a group (12 persons)(15)
|
|
5,612,038
|
|
18.66
|
%
|
*Indicates beneficial
ownership of less than one percent.
**The address of the
directors and named executive officers is Sirtris Pharmaceuticals, Inc.,
200 Technology Square, Cambridge, MA 02139.
(1) The address for FMR
L.L.C. (FMR) is 82 Devonshire Street, Boston, MA 02109. The number of shares
beneficially owned by FMR is as of December 31, 2007, as disclosed in a
Schedule 13G filed with the SEC.
(2) The address for John
W. Henry Trust dated July 20, 1990 is c/o John W. Henry & Company, Inc.,
301 Yamato Road, Suite 2200, Boca Raton, FL 33431. John W. Henry is the
sole beneficiary of the John W. Henry Trust dated July 27, 1990.
23
(3) The address for
Polaris is 1000 Winter Street Waltham, MA 02457. Consists of 2,208,485 shares
held by Polaris Venture Partners IV, L.P. and 36,857 shares held by Polaris
Venture Partners Entrepreneurs Fund, L.P. Polaris Venture Management Co. IV,
L.L.C. is the general partner of Polaris Venture Partners IV, L.P. and may be
deemed to have sole voting and dispositive power with respect to the shares
held by Polaris Venture Partners IV, L.P.
(4) The address for CHP
II, L.P. is 600 Alexander Park, Suite 204, Princeton, NJ 08540. The voting
and investment power over the shares held by CHP II, L.P. is shared among John
Clarke, Brandon H. Hull, Lisa Skeete Tatum, and John J. Park. Mr. Clarke
disclaims beneficial ownership of the shares held by CHP II, L.P., except to
the extent of his pecuniary interest therein.
(5) Consists of 562,257
shares and 212,209 shares of common stock underlying options exercisable within
60 days of April 14, 2008, in addition to 30,476 shares over which Dr. Westphal
may be deemed to have voting and dispositive power due to his position as
trustee of the trusts that hold the shares. Dr. Westphal disclaims
beneficial ownership of the shares held by such trusts.
(6) Consists of 55,000
shares and 179,462 shares of common stock underlying options exercisable within
60 days of April 14, 2008.
(7) Consists of 138,786
shares of common stock and 114,284 shares of common stock underlying options
exercisable within 60 days of April 14, 2008.
(8) Consists of 32,500
shares of common stock and 61,807 shares of common stock underlying options
exercisable within 60 days of April 14, 2008.
(9) Consists of 46,429
shares of common stock and 28,451 shares of common stock underlying options
exercisable within 60 days of April 14, 2008. Additionally, consists of
38,095 shares held by RA Capital Associates. Richard Aldrich is Chairman of RA
Capital Management, LLC, which is affiliated with RA Capital Associates. Mr. Aldrich
disclaims beneficial ownership of shares held by RA Capital Associates, except
to the extent of his pecuniary interest therein.
(10) Consists of
2,073,470 shares held by CHP II, L.P. and 7,619 shares of common stock
underlying options exercisable within 60 days of April 14, 2008. Mr. Clarke shares voting and investment
power over the shares held by CHP II, L.P. and disclaims beneficial ownership
of all shares except to the extent of his pecuniary interest therein.
(11) Consists of
1,268,341 shares held by Skyline Venture Partners Qualified Purchaser Fund III,
L.P., 31,579 shares held by Skyline Venture Partners III, L.P. and 5,543 shares
held by Skyline Venture Management III, L.L.C. and 7,619 shares of common stock
underlying options exercisable within 60 days of April 14, 2008. Dr. Hoffman is a Managing Director of
Skyline Ventures and thereby influences control over these shares. Dr. Hoffman disclaims beneficial
ownership of all shares.
(12) Consists of 19,048
shares of common stock and 55,832 shares of common stock underlying options
exercisable within 60 days of April 14, 2008.
(13) Consists of 73,853
shares of common stock held by Paul Schimmel individually, 76,190 shares held
jointly with Judith Schimmel, 190,476 shares held by Paul Schimmel Prototype
PSP, of which Paul Schimmel is trustee, and 13,571 shares of common stock
underlying options exercisable within 60 days of April 14, 2008.
(14) Consists of 152,834
shares of common stock and 136,308 shares of common stock underlying options
exercisable within 60 days of April 14, 2008.
(15) See footnotes 5-14
above.
24
Securities
Authorized For Issuance Under Equity Compensation Plan
Plan Category
|
|
Number of Securities
to be Issued upon
Exercise of
Outstanding Options,
Warrants or Rights(1)
|
|
Weighted Average
Exercise Price of
Outstanding
Options, Warrants
or Rights
|
|
Number of Securities
Remaining Available for
Future Issuance Under
Equity Compensation
Plan (Excluding
Securities Reflected in
Column (a))(1)(2)
|
|
|
|
(a)
|
|
(b)
|
|
(c)
|
|
|
|
|
|
|
|
|
|
Equity
compensation plans approved by security holders
|
|
3,199,840
|
|
$
|
1.93
|
|
404,445
|
|
|
|
|
|
|
|
|
|
Equity
compensation plans not approved by security holders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
3,199,840
|
|
$
|
1.93
|
|
404,445
|
|
(1) As of December 31,
2007.
(2) Our 2004 Stock
Option Plan (the Plan) includes an evergreen provision that allows for an
annual increase in the number of shares of common stock available for issuance
under the Plan. The annual increase will be added on the first day of each
fiscal year from 2008 through 2013, inclusive, and will be equal to the lesser
of (i) 1,904,762 shares; (ii) 3.5% of the number of then-outstanding
shares of stock; or (iii) a number as determined by the board of
directors. Under this provision, the number of shares of common stock available
for issuance under the Plan increased by 1,006,545 shares on January 1,
2008.
Item 13.
Certain Relationships and Related Transactions and Director Independence
Since January
1, 2007, we have engaged in the following transactions with our directors,
officers, and holders of more than five percent of our voting securities and
their affiliates.
Stock
issuances
Issuance
of Series C-1 redeemable convertible preferred stock
On January 23, 2007 and February 1, 2007, we
sold an aggregate of 21,389,880 shares of our Series C-1 redeemable
convertible preferred stock at a price per share of $1.68 for an aggregate
gross purchase price of approximately $35.9 million. Of these shares, an
aggregate of 15,520,833 shares were sold to the directors, officers, and five
percent stockholders and each of their respective affiliates set forth in the
table below. All shares of our Series C-1 redeemable convertible preferred
stock were automatically converted into 4,074,260 shares of our common stock
upon the completion of our initial public offering in May 2007.
Name
|
|
Relationship
|
|
Series C-1
preferred stock
|
|
Purchase price
|
|
|
|
|
|
|
|
|
|
John W. Henry
Trust dated July 27, 1990
|
|
5% Stockholder
|
|
11,904,762
|
|
$
|
20,000,000
|
|
TVM V Life
Science Ventures GmbH & Co. KG(1)
|
|
5% Stockholder
|
|
1,785,714
|
|
3,000,000
|
|
Funds managed by
Skyline Venture Management(2)
|
|
5% Stockholder
|
|
1,190,476
|
|
2,000,000
|
|
Funds managed by
Three Arch Management(3)
|
|
5% Stockholder
|
|
595,238
|
|
1,000,000
|
|
David Sinclair
|
|
Director
|
|
14,881
|
|
25,000
|
|
Christoph
Westphal
|
|
Officer and Director
|
|
14,881
|
|
25,000
|
|
Peter Elliott
|
|
Officer
|
|
14,881
|
|
25,000
|
|
TOTAL
|
|
|
|
15,520,833
|
|
$
|
26,075,000
|
|
(1) TVM V Life
Science Ventures Management GmbH & Co. KG is the Managing Limited
Partner and investment committee of TVM V Life Science Ventures GmbH &
Co. KG. Stephen Hoffman, one of our directors, was was a senior advisor to TVM
V Life Science Ventures Management GmbH & Co. KG.
25
(2) Consists of
1,161,556 shares held by Skyline Venture Partners Qualified Purchaser Fund III,
L.P. and 28,920 shares held by Skyline Venture Partners III, L.P. Skyline
Venture Management III, LLC is the general partner of Skyline Venture Partners
Qualified Purchaser Fund III, L.P. and Skyline Venture Partners III, L.P. John
Freund, a former director, and Stephen Hoffman, a current director, are both
Managing Directors of Skyline Venture Management III, LLC.
(3) Consists of
582,379 shares held by Three Arch Partners IV, L.P. and 12,859 shares held by
Three Arch Associates IV, L.P. Three Arch Management IV, LLC, is the General
Partner for Three Arch Partners IV, LP and Three Arch Associates IV, LP.
Wilfred Jaeger, a former director, is a member of Three Arch Management IV,
LLC.
Registration
rights
Certain directors, officers, stockholders and warrant
holders are entitled to require us to register their shares or participate in a
registration of shares by us under the Securities Act. These rights are
provided under the terms of various agreements between us and the holders of
these shares and warrants. These holders include the following directors,
officers, and holders of more than five percent of our voting securities and
their affiliates:
Name
|
|
Relationship
|
|
Number of
registrable shares
|
|
|
|
|
|
|
|
John W. Henry Trust
dated July 27, 1990(1)
|
|
5% Stockholder
|
|
2,267,573
|
|
Funds managed by
Polaris Venture Partners(2)
|
|
5% Stockholder
|
|
2,245,342
|
|
TVM V Life
Science Ventures GmbH & Co. KG(3)
|
|
5% Stockholder
|
|
2,577,438
|
|
CHP II, L.P.(4)
|
|
5% Stockholder
|
|
2,073,469
|
|
Funds managed by
Skyline Venture Management(3)
|
|
5% Stockholder
|
|
1,846,145
|
|
Funds managed by
Three Arch Management(3)
|
|
5% Stockholder
|
|
1,672,902
|
|
Paul Schimmel(5)
|
|
Director
|
|
354,090
|
|
David Sinclair
|
|
Director
|
|
289,142
|
|
Christoph
Westphal
|
|
Officer and Director
|
|
804,942
|
|
Peter Elliott
|
|
Officer
|
|
253,070
|
|
|
|
|
|
|
|
TOTAL
|
|
|
|
14,384,113
|
|
(1) John W. Henry is the
sole beneficiary of the John W. Henry Trust dated July 27, 1990.
(2) Consists of 2,208,485
shares held by Polaris Venture Partners IV, L.P. and 36,587 shares held by
Polaris Venture Partners Entrepreneurs Fund IV, L.P. Alan Crane, a former
director, is a Venture Partner at Polaris Venture Partners.
(3) Based on the
publicly available filings, TMV Life Science Ventures Management GmbH & Co.
KG, funds managed by Skyline Venture Management and funds managed by Three Arch
Management are not currently five percent holders of our securities. As of
January 23, 2007, the date of the Fourth Amended and Restated Registration
Rights Agreement among certain investors and us, each entity held more than
five percent of our securities. The
number of registrable shares listed for these parties in the table above is as
of January 23, 2007.
(4) CHP II
Management, LLC is the sole General Partner of CHP II, L.P. John Clarke, one of
our directors, is a managing member of CHP II Management, LLC.
(5) Consists of
73,853 shares of common stock held by Paul Schimmel individually, 76,190 shares
held jointly with Judith Schimmel, 190,476 shares held by Paul Schimmel Prototype
PSP, of which Paul Schimmel is trustee and 13,571 shares of common stock
underlying options exercisable within 60 days of April 14, 2008.
26
Indemnification
agreements
We have entered into indemnification agreements with
each of our current directors to give such directors additional contractual
assurances regarding the scope of the indemnification set forth in the Companys
certificate of incorporation and bylaws and to provide additional procedural
protections.
Employment
agreements
We have entered into employment agreements with our
executive officers. For a detailed description of these employment agreements,
see Executive CompensationEmployment Agreements.
Director
and executive officer compensation
Please see Director Compensation for a discussion of
options granted and payments made to our non-employee directors. Please see Executive
Compensation Summary Compensation Table, Executive Compensation Grants of
Plan-Based Awards Table and Compensation Discussion & Analysis Long-Term
Incentives for additional information regarding compensation of our executive
officers.
Review
and approval of related party transactions
The Nominating and Corporate Governance Committee reviews
and approves transactions with directors, officers, and holders of more than
five percent of our voting securities and their affiliates, or each, a related
party in consultation with the Chief Executive Officer and Chief Operating
Officer. Prior to consideration of a transaction with a related party, the
material facts as to the related partys relationship or interest in the
transaction are disclosed to the Committee, and the transaction is not
considered approved by the Committee unless a majority of the directors who are
not interested in the transaction approve the transaction. All related party
considerations and decisions are documented in the Nominating and Corporate and
Governance Committee minutes.
Item 14.
Principal Accounting Fees and Services
The firm of Ernst & Young LLP, independent
auditors, has been selected by the Audit Committee as auditors for Sirtris for
the fiscal year ending December 31, 2008. Ernst & Young LLP acted
as independent auditors for Sirtris for the year ended December 31, 2007.
The
following table shows information about fees paid by Sirtris to Ernst &
Young LLP during the fiscal years ended December 31, 2007 and 2006.
|
|
Fiscal Year
2007
|
|
Percentage of 2007
Services Approved by
Audit Committee (1)
|
|
Fiscal Year
2006
|
|
Percentage of 2006
Services Approved by
Audit Committee (1)
|
|
Audit fees(2)
|
|
$
|
623,000
|
|
100
|
%
|
$
|
38,000
|
|
0
|
%
|
Audit-related
fees
|
|
$
|
|
|
100
|
%
|
$
|
|
|
0
|
%
|
Tax fees
|
|
$
|
|
|
100
|
%
|
$
|
|
|
0
|
%
|
All other fees
|
|
$
|
|
|
100
|
%
|
$
|
|
|
0
|
%
|
Total
fees
|
|
$
|
623,000
|
|
100
|
%
|
$
|
38,000
|
|
0
|
%
|
(1) The
Company went public on May 29, 2007 and did not perform Audit Committee
pre-approval processes for services provided by independent auditors before
that time.
(2) Audit fees
in 2007 include fees in the amount of $450,000 for the Companys registration
statement on Form S-1, related comfort letters, consents and responding to
SEC comment letters.
27
The Audit Committees policy is to approve all audit
and non-audit services provided by our independent auditor prior to the
commencement of the services using a combination of pre-approvals for certain
engagements up to predetermined dollar thresholds in accordance with the
pre-approval policy and specific approvals for certain engagements on a
case-by-case basis. The Audit Committee has delegated authority to the Chairman
to pre-approve between committee meetings services that have not already been
pre-approved by the committee. The Chairman is required to report any such
pre-approval decisions to the full committee at its next scheduled meeting.
AUDIT COMMITTEE REPORT
The Audit Committee has reviewed the Companys audited
financial statements for the fiscal year ended December 31, 2007 and has
discussed these statements with management and Ernst & Young LLP, the
Companys independent registered public accounting firm. The Companys
management is responsible for the preparation of the Companys financial
statements and for maintaining an adequate system of disclosure controls and
procedures and internal control over financial reporting for that purpose.
Ernst & Young LLP is responsible for expressing an opinion on the
conformity of the audited financial statements with generally accepted
accounting principles, their judgments as to the quality, not just the
acceptability, of the Companys accounting principles and such other matters as
are required to be discussed with the Audit Committee under generally accepted
auditing standards. The Audit Committee is responsible for providing
independent, objective oversight of the Companys accounting functions and
internal controls.
The Audit Committee also received from, and discussed
with, Ernst & Young LLP the written disclosures and other
communications that the Companys independent registered public accounting firm
is required to provide to the Audit Committee, including the matters required
to be discussed by Statement on Auditing Standards 61 (Communication with Audit
Committees), which we refer to as SAS 61. SAS 61 (as codified in AU Section 380
of the Codification of Statements on Auditing Standards) requires our
independent registered public accounting firm to discuss with the Audit
Committee, among other things, the following:
·
methods
to account for significant unusual transactions;
·
the
effect of significant accounting policies in controversial or emerging areas
for which there is a lack of authoritative guidance or consensus;
·
the
process used by management in formulating particularly sensitive accounting
estimates and the basis for the independent registered public accounting firms
conclusions regarding the reasonableness of those estimates; and
·
disagreements
with management regarding financial accounting and reporting matters and audit
procedures.
Ernst & Young LLP also provided the Audit
Committee with the written disclosures and the letter required by Independence
Standards Board Standard No. 1 (Independence Discussions with Audit
Committees). Independence Standards Board Standard No. 1 requires
independent registered public accounting firms annually to disclose in writing
all relationships that in their professional opinion may reasonably be thought
to bear on independence, to confirm their perceived independence and engage in
a discussion of independence. The Audit Committee has reviewed this disclosure
and has discussed with Ernst & Young their independence from Sirtris.
Based on its discussions with management and our
independent registered public accounting firm, and its review of the
representations and information provided by management and our independent
registered public accounting firm, the Audit Committee recommended to the Board
of Directors that the audited financial statements be included in the Companys
Annual Report on Form 10-K for the fiscal year ended December 31,
2007, for filing with the Securities and Exchange Commission.
|
Respectfully
submitted by the
|
|
Audit Committee,
|
|
Jeffrey Capello
|
|
John Clarke
|
|
Paul Schimmel
|
28
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
|
SIRTRIS
PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/
CHRISTOPH WESTPHAL
|
|
|
Christoph
Westphal
|
|
|
President, Chief
Executive Officer and Vice Chairman
|
|
|
|
|
|
|
Date: April 29,
2008
|
|
29
SIRTRIS
PHARMACEUTICALS, INC.
FORM 10-K/A
December 31, 2007
INDEX
OF EXHIBITS
Exhibit No.
|
|
Description
|
|
|
|
31.1
|
|
Certification
of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002.
|
|
|
|
31.2
|
|
Certification
of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002.
|
|
|
|
32.1
|
|
Certification Pursuant
to Section 1350, Chapter 63 of title 18, United States Code, as adopted Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002.
|
30
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Apr 2024 to May 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From May 2023 to May 2024